Joint Commission International (JCI) supports hospitals, health systems and clinics in achieving a greater level of performance excellence for those they serve through our expansive portfolio of quality improvement products and services.
No matter where your organization may be today in its journey toward safe, consistent care we can help you continue to advance and excel.
Learn why thousands of organizations just like yours have chosen JCI to help them build, standardize, and strengthen essential processes —earning our coveted Gold Seal of Approval®, a universally recognized symbol of striving to achieve a higher bar in quality and patient safety.
Our Portfolio:
• Accreditation and Certification
• Advisory Services
• Education Programs
• High Reliability Services
• Patient Safety Pathways
Elevating Patient Care. Together.
LEARN MORE:
THE MODERN HOSPITAL: BEYOND WALLS & BORDERS
A hospital that reaches you before you arrive… and cares for you long after you leave. The role of the hospital has undergone a profound transformation. What was once a place to receive treatment has now become a partner in health, a hub of knowledge, and a vital pillar of the community. Hospitals today are no longer confined by their walls; their mission begins before illness strikes and continues well beyond recovery.
The modern philosophy of care is rooted in prevention. Telemedicine, remote monitoring, and home-care programs now allow doctors and nurses to reach patients wherever they are. Instead of traveling to the hospital, patients can access consultations, support, and even treatment from the comfort of their homes. This shift reflects a simple truth: protecting health starts long before the first hospital visit. This new model extends across two essential dimensions, prevention and continuity of care. By fostering a culture of prevention, hospitals help shield communities from epidemics and chronic diseases, sparing countless individuals from hospitalization altogether. Global research confirms that preventive measures have the power to reduce illness on a massive scale.
Equally vital is follow-up care after discharge. By continuing treatment and monitoring at home, hospitals reduce costs, free up resources, and ensure that other patients in need can be treated promptly. For the patient, the benefits are even greater: comfort, convenience, and the reassurance of ongoing support. Where once a patient’s connection to the hospital began at admission and ended at discharge, today that relationship is continuous. Hospitals have evolved into full partners in social well-being, safeguarding health before, during, and after illness.
The
Publisher
Publisher Arab Health Media Communication
President Simon Chammas schammas@tahmag.com
Executive Vice President Mirna Khairallah mirna@tahmag.com
Baylor St. Luke’s Medical Center is nationally recognized for its commitment to providing high-quality stroke care
40 Bilal Muhsin, Executive Vice President and President of Future Connected Care Segment
82
Dr. Moataz Suleiman, Head of Dermatology Department at Cosmesurge Clinics in the UAE
74
Empowering Women in the Fight Against Breast Cancer
MEDICAL INSTITUTIONS
8 Baylor St. Luke’s Medical Center is nationally recognized for its commitment to providing high-quality stroke care
28 KERN & SOHN obtains MDR certification for medical scales
60 Apex Health Secures Five Prestigious Awards for Patient Experience Excellence from Arab Hospitals Federation
64 UChicago Medicine emerges as a global leader in focal therapy treatments for prostate cancer
66 Human bone archive sparks clinical innovation for UCLA Cochlear Implant Program
68 A Center Exclusively Focused on Breast Cancer Treatment: Acıbadem Breast Cancer Clinic
98 Acıbadem Healthcare Group... Two Babies with Liver Failure from Georgia and Libya Treated in Türkiye
118 Traveling to Türkiye for Prostate Cancer Treatment: What Acıbadem Offers
INTERVIEWS
40 Bilal Muhsin, Executive Vice President and President of Future Connected Care Segment
78 Miriana Hijaz, MD FACOG FACS, Division Director of Gynecologic Oncology | Women's Health Services, Henry Ford Health
82 Dr. Moataz Suleiman, Head of Dermatology Department at Cosmesurge Clinics in the UAE
94
KSA healthcare sector emerges as an international hub for attracting capital
86 Dr. Shirin Muhsen, Vice President of The Quality Department and a Specialist in Breast and Colorectal Tumor Surgery at Clemenceau Medical Center-Beirut
106 Professor Ali Taher, Lebanese Professor Leads Breakthrough in Thalassemia Treatment
110 Renée-Marie Stephano, CEO, Global Healthcare Accreditation
ARTICLES
52 Mecomed: Unlocking Access Through Better Coding… Priorities for Medical Devices and In-Vitro Diagnostics in Saudi Arabia’s Healthcare System
70 Al-Ahli Hospital: Speech & Language Therapy: Empowering Children with ADHD
116 Al-Ahli Hospital: Protecting Women’s Health: The Critical Role of HPV Vaccination
FEATURES
56 Advanced Healthcare Infrastructure
74 Empowering Women in the Fight Against Breast Cancer
90 Effective Management Strategies for Post-Stroke Hemiplegia
94 The Saudi healthcare sector emerges as an international hub for attracting capital
Baylor St. Luke’s Medical Center is nationally recognized for its commitment to providing high-quality stroke care
Stroke is the No. 5 cause of death and a leading cause of disability in the U.S. Early stroke detection and treatment are key to improving survival, minimizing disability and accelerating recovery times.
Baylor St. Luke’s has received the American Heart Association’s Get With The Guidelines® - Stroke Gold Plus quality achievement award for its commitment to ensuring stroke patients receive the most appropriate treatment according to nationally recognized, researchbased guidelines, ultimately leading to more lives saved and reduced disability.
Get With The Guidelines puts the expertise of the American Heart Association and American Stroke Association to work for hospitals nationwide, helping ensure patient care is aligned with the latest research- and evidencebased guidelines. Get With The GuidelinesStroke is an in-hospital program for improving stroke care by promoting consistent adherence to these guidelines, which can minimize the longterm effects of a stroke and even prevent death.
Baylor St. Luke’s also received the American
Heart Association’s Target: StrokeSM Honor Roll Elite Plus award for meeting specific criteria that reduce the time between an eligible patient’s arrival at the hospital and treatment with thrombolytic therapy.
In addition, Baylor St. Luke’s received the American Heart Association’s Target: StrokeSM Honor Roll Advanced Therapy award by meeting specific criteria that reduce the time between an eligible patient’s arrival at the hospital and treatment to remove the clot causing the stroke.
Baylor St. Luke’s also received the American Heart Association’s Target: Type 2 Honor Roll award, which aims to ensure patients with Type 2 diabetes receive the most up-to-date, evidencebased care when hospitalized due to stroke.
The hospital also received the American Heart Association’s Resuscitation Award Silver –Adult and the Target: CPR Resuscitation Award.
BAYLOR ST. LUKE’S HAS RECEIVED THE AMERICAN HEART ASSOCIATION’S GET WITH THE GUIDELINES® - STROKE GOLD PLUS QUALITY ACHIEVEMENT AWARD.
A n exc e ptio n al g ro u p devote d to
ACIBADEM MOBIL
provides emergency and home care services outside of the hospital.
ACIBADEM APLUS
addresses the hygiene and catering requirements of the hospitals.
ACIBADEM HEALTH POINT ensures continuous support for patients from their arrival at Istanbul Airport until they return home, guiding them through their entire healthcare journey in Türkiye.
ACIBADEM TECHNOLOGY
develops and improves inhouse softwares including Hospital Information System and healthcare command center.
ACIBADEM UNIVERSITY
trains healthcare students to be future healthcare professionals.
ACIBADEM LABMED
offers a wide range of services including pathology, food control, stem cell and cord blood bank within the laboratory framework.
develops turnkey hospital establishment projects.
Unveiling ACIBADEM Healthcare Ecosystem
Step into a world where healthcare is not just a service, but a carefully designed ecosystem centered around Patient Safety and Patient Satisfaction – Welcome to ACIBADEM. At the forefront of innovative medical care, ACIBADEM's healthcare model is a testament to its unwavering commitment to excellence. Every facet of the healthcare journey is seamlessly integrated, with ACIBADEM collaborating with its supporting institutions at every step to mitigate risks and ensure service quality that aligns with ACIBADEM standards. Embark on a journey of cutting-edge medical services that transcend borders, as ACIBADEM extends its reach across Türkiye, Bulgaria, Macedonia, Serbia, and the Netherlands. Experience healthcare like never before, where your well-being takes center stage.
10 Years in a Row on the ' Best Hospitals ' Honor Roll in the U.S.
Cedars-Sinai has been named to the Honor Roll for the 10th consecutive year and tied for No. 1 in California and Los Angeles in U.S. News & World Report’s “Best Hospitals 2025-26” rankings.
Every year, thousands of patients from over 100 countries choose Cedars-Sinai for our renowned healthcare. From complex surgeries to rare diagnoses and second opinions, the Cedars-Sinai team ensures a seamless experience - before, during, and after care.
Six Cedars-Sinai specialties were ranked in the top 10 in the U.S.:
Orthopedics
Obstetrics & Gynecology
Diabetes & Endocrinology
Pulmonology & Lung Surgery
Gastroenterology & GI Surgery
Cardiology, Heart & Vascular Surgery
Located in Los Angeles, California, Cedars-Sinai combines world-class care with a vibrant setting, cultural sensitivity, and concierge-level comfort.
The world’s premier center for transplant oncology
As a world-class transplant center, Northwestern Medicine’s programs and procedures are saving more lives than ever. With an ideal Downtown Chicago location and dedicated global services team, physicians can feel confident sending patients and their families to Northwestern Medicine for quality care in a dynamic, connected city.
n Top-ranked U.S. transplant center with 400+ annual transplants and exceptional outcomes
n Personalized coordination, care, and concierge services from Global Services Team at every step of the journey
n Chicago location offers daily direct flights, ultra-luxury shopping and five-star dining, plus activities for visitors of all ages
n Home to first and only transplant program for lung cancer patients, as well as liver transplant program for late-stage colorectal cancer patients
n Average 5-day evaluation
n Shortest median wait time from listing to transplant
n Decreased risk of organ rejections
n Superior success rates one year after transplant
Through groundbreaking techniques and programs, Northwestern Medicine is performing more lung transplants than ever — with 148 completed in 2024, the highest number by any program in the country. Transplantation is now an option for late-stage lung cancer patients through our clinical program, DREAM (Double Lung Transplant Registry Aimed for Lung-Limited Malignancies). Learn
KERN & SOHN obtains MDR certification for medical scales
KERN & SOHN GmbH has obtained MDR certification for its medical scales. This means that products from the Southern German family business now officially fulfil the requirements of the European Medical Device Regulation (MDR), EU 2017/745. The MDR replaces the previous MDD Directive and is considered to be much stricter regarding quality assurance, patient safety and traceability. Both KERN's quality management system and the technical documentation of the products were comprehensively audited during the multi-stage certification process. The company passed both audits without any non-conformance – a result that is considered exceptional in the industry.
Reliability for medical users in Europe and the Middle East
With the MDR certification, KERN documents that its medical personal, chair, wheelchair and baby scales fulfil all the current legal requirements. Users in clinics, medical practices and care institutions can rely on tried-andtested safety and the long-term availability of MDR-compliant products.
"The MDR certification is an important milestone for KERN. It highlights our ongoing commitment to quality, safety and regulatory compliance in the healthcare sector," explains Managing Director Albert Sauter.
The changeover to MDR-certified scales is seamless at KERN: Orders already placed and new orders will automatically be fulfilled with appropriately labelled products. Updates to labels and packaging are handled internally.
Reinforcing commitment to the Arab healthcare market
Last year, KERN also received approval from the Saudi Food and Drug Authority (SFDA) for its Premium Line. This portfolio includes personal floor scales, baby scales and chair scales, which are characterized by outstanding precision, user-friendliness and easy integration into hospital and practice systems.
With MDR certification in Europe and SFDA approval in Saudi Arabia, KERN strengthens its international presence and reliability for healthcare professionals. The company is working closely with local partners in the Middle East to ensure the best possible support for hospitals, clinics, and scientific institutions.
About KERN
For over 180 years, KERN & SOHN GmbH, with its registered office in Balingen, BadenWürttemberg, has been synonymous with the highest level of precision and reliability in measuring and weighing technology. In 1844, the company founder, Gottlieb Kern, developed the most precise balances of his time – a claim which drives the continuous development of this family business to this day. The range now covers more than 5,000 products, including balances, test weights, microscopes and measuring devices for professional use in the laboratory, medical and industrial sectors and commerce. The range is supplemented by software solutions as well as calibration and test services.
www.kern-sohn.com
KERN & SOHN GmbH, Ziegelei 1, 72336 Balingen, Germany, info@kern-sohn.com
WITH THE MDR CERTIFICATION, KERN DOCUMENTS THAT ITS MEDICAL PERSONAL, CHAIR, WHEELCHAIR AND BABY SCALES FULFIL ALL THE CURRENT LEGAL REQUIREMENTS. USERS IN CLINICS, MEDICAL PRACTICES AND CARE INSTITUTIONS CAN RELY ON TRIED-ANDTESTED SAFETY AND THE LONG-TERM AVAILABILITY OF MDR-COMPLIANT PRODUCTS.
KERN & SOHN GmbH has obtained MDR certification for its medical scales, including the KERN MBA baby scale. (Image: KERN & SOHN)
Hope begins with innovation and personalized cancer care.
Henry Ford Health, driving innovative healthcare for over a century.
We are creating more hope for patients around the world. With one unified team of specialists and innovations ranging from precision medicine to advanced radiation therapy, we deliver one-of-a-kind cancer treatments—crafted precisely for you. Henry Ford Health is one of the world’s leading comprehensive, integrated health systems, recognized for our clinical excellence.
The Modular Hospital
A hospital model that adapts, grows, and transforms
The Modular Hospital in Benghazi is a strategic, new generation healthcare project that was designed to adapt, grow, and transform in line with the needs of the population. Due to its modular and scalable architecture, the facility has the capacity to expand from its initial configuration of 100 beds to 250 beds, while maintaining high efficiency standards, safety, and quality of care. It covers more than 20,000 m² across four levels, encompassing a comprehensive range of clinical and diagnostic services. These include emergency department, outpatient clinics, advanced imaging, intensive care units, operating theatres (including hybrid ORs), central pharmacy, dialysis and endoscopy units, physiotherapy areas, as well as support functions such as a canteen and auditorium. What truly sets this project apart is its flexibility. Here, new medical functions can be progressively integrated alongside the
BY COMBINING ADAPTABILITY, SCALABILITY, AND RESILIENCE, THE BENGHAZI FACILITY OFFERS A BLUEPRINT FOR FUTURE-READY HEALTHCARE SYSTEMS, ESPECIALLY IN REGIONS WHERE NEEDS ARE CONSTANTLY CHANGING AND INCREASING.
increase in bed capacity, ensuring a flexible and sustainable development model. Circulation flows are also carefully organized to separate patients, staff, clean and dirty materials, in full compliance with international hygiene and safety protocols. By combining adaptability, scalability, and resilience, the Benghazi facility offers a blueprint for future-ready healthcare systems, especially in regions where needs are constantly changing and increasing.
A New Era in Breast Cancer Care... Lebanon Introduces Breakthrough Targeted Therapy Ahead of Pink October
As Lebanon prepares for Pink October, the international breast cancer awareness month, a breakthrough targeted therapy for advanced HER2-positive and HER2-low breast cancer is registered and launched in the country, helping patients with advanced HER2positive breast cancer who have historically faced a poor prognosis and limited management options, as resistance to standard therapies and disease progression have long challenged effective long-term outcomes.
“The diagnosis of breast cancer in Lebanon remains a major concern, reflected in both the high incidence rates and the need for sustained early detection programs,” said Dr. Roger Khater, Hematologist-oncologist, Head of the Lebanese Society of Medical oncology.
“Through the Lebanese Society of Medical Oncology, we continue to advance the expertise of our oncology community, ensuring that care in Lebanon remains aligned with the latest international standards and scientific developments. By collaborating closely with local authorities, we are working to secure timely access to innovative medications across the country. The launch of this breakthrough therapy exemplifies the resilience and progress of our health sector, marking a critical step in integrating world-class innovation into the care of Lebanese patients.”
Breast cancer is the most frequently diagnosed cancer among Lebanese women, accounting for 33.6% of new cases in females and 16.6% of all cancer cases across both sexes in Lebanon¹. In 2022 alone, the country recorded 2,161 new breast cancer cases and 781 related deaths¹. More than 6,800 women in
Lebanon are currently living with breast cancer diagnosed within the past five years, reflecting a substantial patient population and an urgent need for continued innovation¹.
While ongoing awareness campaigns, screening efforts, and advances in care have contributed to earlier detection and improved outcomes², breast cancer remains the leading malignancy and a major cause of cancer-related mortality in Lebanon. Up to 60% of metastatic breast cancer cases globally are classified as HER2-low, a segment that previously lacked dedicated treatment options³.
This newly approved HER2-directed antibody-drug conjugate (ADC), developed by AstraZeneca in collaboration with Daiichi Sankyo, is the first therapy specifically designed to target both HER2-positive and HER2-low/ Ultralow disease. It uses advanced ADC technology: binding to HER2 proteins on cancer cells and releasing chemotherapy directly inside the cell, enhancing effectiveness while limiting damage to surrounding healthy tissue⁴⁵.
For Lebanese patients and clinicians, this marks the arrival of personalized, targeted treatment options for women who urgently need more hope and the chance for longer, better lives⁶. The positive impact of this therapy has been confirmed in global clinical trials such as DESTINY-Breast03, DESTINYBreast04, and DESTINY-Breast12, which demonstrated significant improvements in progression-free and overall survival for HER2positive and HER2-low / Ultralow patients compared with standard therapies⁵.
Introducing this therapy in Lebanon signals a new era in breast cancer care, anchored in robust clinical evidence and aligned with international guidelines⁵⁶.
At the new treatment’s launch event, Lebanon’s Breast Cancer Oncology leaders shared their perspectives: Prof. George Chahine, Professor of Hematology & Oncology, Hôtel-Dieu de France
BREAST CANCER IS THE MOST FREQUENTLY DIAGNOSED CANCER AMONG LEBANESE WOMEN, ACCOUNTING FOR 33.6% OF NEW CASES IN FEMALES AND 16.6% OF ALL CANCER CASES ACROSS BOTH SEXES IN LEBANON¹. IN 2022 ALONE, THE COUNTRY RECORDED 2,161 NEW BREAST CANCER CASES AND 781 RELATED DEATHS¹.
REFERNECES
1. Global Cancer Observatory: Cancer Today (GLOBOCAN 2022, Lebanon Fact Sheet), International Agency for Research on Cancer, February 2024.
2. World Health Organization (WHO). Lebanon: Cancer Profile 2022.
3. Modi et al., "Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer," New England Journal of Medicine, 2022; 387:9-20.
5. U.S. FDA Enhertu Approval (August 2022), EMA Press Release (2023), and DESTINY-Breast04 Clinical Trial, NEJM 2022.
6. Lebanese National Cancer Registry, Ministry of Public Health, 2022 Annual Report.
in Beirut: “The management of breast cancer, and particularly metastatic cases, remains a complex challenge due to disease progression and limited treatment options. The approval of this innovative targeted therapy gives new hope to patients and their families, ushering in a new era of personalized care and significantly improving outcomes for women with HER2-positive and HER2-low subtypes who previously had fewer options.”
Prof. Peter Fasching, Associate Professor of Gynecology and Obstetrics and Translational Medicine at the FriedrichAlexander University Erlangen-Nuremberg and the National Center for Tumor Diseases WERA in Erlangen, Germany: “International collaboration plays a vital role in driving progress for breast cancer management, ensuring that scientific breakthroughs are quickly translated into real-world benefits for patients everywhere. The arrival of innovative medications such as HER2-directed therapies marks a new era, one that offers genuine hope for women facing advanced and metastatic disease. With these advances, we are seeing significant reductions in disease progression and cancer-related death, reaffirming the importance of global research partnerships and access to modern treatments for improved outcomes and quality of life.”
Rami Scandar, Country President for the Near East and Maghreb Region at AstraZeneca: “AstraZeneca is proud to accelerate the registration and supply of transformative solutions in Lebanon, even in challenging environments. The introduction of this breakthrough targeted therapy, just ahead of Pink October, is a testament to our collaboration with Lebanese health authorities and medical experts, and to our commitment to supporting patients with science recognized in global guidelines.
“AstraZeneca reiterates its support for Lebanon, partnering with healthcare authorities and oncology communities to deliver cutting-edge therapies that improve survival and quality of life for Lebanese women facing breast cancer.”
Precision weighing solutions for hospitals, clinics and care facilities. EU MDR certified and SFDA approved.
www.kern-sohn.com
Dubai Health Welcomes the Tenth Cohort into the Doctor of Medicine program
Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), the learning and discovery arm of Dubai Health, welcomed its tenth cohort into the Doctor of Medicine program with a White Coat Ceremony. This event is a deeply symbolic tradition for medical students during which they take the Hippocratic Oath, marking the beginning of their academic and professional journey and reinforcing the values of commitment and professional ethics throughout their studies. The ceremony was attended by Dr. Amer Sharif, CEO of Dubai Health and President of MBRU; Dr. Hanan Al Suwaidi, Acting Chief Academic Officer at Dubai Health and Acting Provost at MBRU; Professor Suleiman Al-Hammadi, Dean of the College of Medicine at MBRU; and Dr. Laila Al Suwaidi, Dean of Student Affairs at MBRU, along with MBRU faculty members, students, and their parents.
Dr. Amer Sharif congratulated the students on reaching this important milestone in their academic journey, emphasizing that MBRU leads the learning and discovery missions of Dubai’s first integrated academic health system, Dubai Health. He also introduced a new tradition, the Patient First Pinning Ceremony. As the primary value of Dubai Health, wearing the Patient First pin on the white coats underscores the students’ commitment to placing patients at the center of their medical practice, and serves as a reminder of the university’s core values: Respect, Excellence, Teamwork, Integrity, and Empathy.
Since its launch in 2016, the Doctor of Medicine program at Mohammed Bin Rashid University of Medicine and Health Sciences has graduated 170 doctors, many of whom have joined residency and fellowship programs both within the UAE and abroad. The six-year program combines medical education with clinical training and scientific research.
Dr. Hanan Al Suwaidi said: “The White Coat Ceremony, now in its tenth edition, represents an important milestone in the journey of our new students and reflects the university’s ongoing commitment to developing medical professionals
who contribute to serving the community and enhancing the quality of healthcare in Dubai and across the UAE.” She added: “Through our integrated academic health system, we ensure a connection between education, clinical practice, and scientific research, providing our students with the knowledge and experience that strengthen their skills and elevate their capabilities. Over the past ten years, we take pride in supporting the healthcare sector with highly qualified medical professionals across various specialities, contributing to the advancement of the health system.”
Dean Suleiman Al-Hammadi said: “The tenth cohort of the Doctor of Medicine program represents a continuation of the journey that began in 2016, followed by our graduates’ progression into residency and specialty programs. This new cohort continues this advanced academic path, contributing to the preparation of physicians qualified to enhance the quality of medical services.”
Dean Laila Al Suwaidi said: “The new cohort ceremony is a moment of pride that renews each year and reflects the university’s commitment to guiding medical students from their first day until they graduate as distinguished physicians. We are dedicated to providing a supportive and inclusive environment that expands knowledge, develops talent, and equips students with the skills to advance healthcare and serve the community.”
THE CEREMONY WAS ATTENDED BY DR. AMER SHARIF, CEO OF DUBAI HEALTH AND PRESIDENT OF MBRU; DR. HANAN AL SUWAIDI, ACTING CHIEF ACADEMIC OFFICER AT DUBAI HEALTH AND ACTING PROVOST AT MBRU; PROFESSOR SULEIMAN AL-HAMMADI, DEAN OF THE COLLEGE OF MEDICINE AT MBRU; AND DR. LAILA AL SUWAIDI, DEAN OF STUDENT AFFAIRS AT MBRU, ALONG WITH MBRU FACULTY MEMBERS, STUDENTS, AND THEIR PARENTS.
NEWTOM 7G Wide.Vision Cutting-edge cbct
NEWTOM CBCT IMAGING NOW DRAWS ON FRESH ENERGY
As of today NEWTOM 7G incorporates the Dual Energy (DE) system, elevating performance to new heights and revolutionising the way your practice operates.
Dual Energy: patented NEWTOM technology
The result of a continuous quest for patient well-being and ever-greater diagnostic precision, Dual Energy uses two different radiant energies to identify any pathologies with greater clarity and precision.
Virtual Monochromatic Images
Dual Energy technology mitigates beam-hardening artifacts. What’s more, being able to reconstruct monochromatic virtual images at different keVs improves soft tissue imaging quality and reduces metal artifacts. Lastly, Dual Energy CBCT provides a basis for tissue characterisation.
Colour-coded images
NEWTOM Dual Energy software enables users to perform semi-automatic tissue segmentation and apply colour codes, streamlining the differentiation of materials within the scanned area. This allows rapid and straightforward detection of potential pathologies.
Blended image
The new features enable weighted blending of high- and low-energy imaging. The resulting images combine the low noise, typical of high-energy acquisition, with the high contrast resolution of the low-energy image set.
Featuring a large gantry aperture, the NEWTOM 7G is the most advanced CBCT device on the market. From in-depth detail to the big picture.
Shaping the Future of MedTech in the Middle East & Africa
Mecomed is the Medical Technology Association of the Middle East & Africa, uniting leading manufacturers and their partners to:
• Advance patient access to innovative healthcare solutions.
• Foster ethical business practices and compliance.
• Build strong partnerships with regulators and other stakeholders.
• Support digital transformation and healthcare innovation.
• Enhance MedTech industry and healthcare professionals’ expertise in regulations, ethics, compliance, market access, and digital health.
Together, we are driving a sustainable health ecosystem that empowers better patient outcomes across the region.
KFSHRC Participated in C3 Davos of HealthcareTM Japan Summit
King Faisal Specialist Hospital and Research Centre (KFSHRC) participated in the C3 Davos of Healthcare™ Japan Summit, that took place on September 24, 2025 under the theme “A Tri-Nation Collaboration: Building Bridges Beyond Borders in Healthcare,” bringing together global leaders, policymakers, investors, and innovators to foster international dialogue and collaboration. At the heart of KFSHRC’s delegation is H.E. Dr. Majid Alfayyadh, Saudi Royal Court Advisor and CEO of King Faisal Specialist Hospital & Research Centre, delivered a keynote address titled “King Faisal’s Vision for Integrated Healthcare & Investing in a New Infrastructure for Modern Medicine.”
In his address, Dr. Alfayyadh presented the Kingdom’s strategy for building a connected and patient-centered healthcare ecosystem, highlighting initiatives in digital health, hospital expansions, and medical education. He also addressed how public-private partnerships, foreign investments, and regulatory reforms are shaping Saudi Arabia’s healthcare future, offering insights into the Kingdom’s ambitious plans and opportunities for global collaboration.
As part of the program, KFSHRC thought leaders engaged in strategic discussions on healthcare transformation. Dr. Esam Abdullah Al Banyan, Chief Education & Training Officer at KFSHRC, participated in a session titled “How the US & Japan Can Contribute to Saudi Arabia’s Vision 2030 in Healthcare”, where he explored opportunities for collaboration in biotechnology, robotics, and aging care.
Dr. Osama AlSwailem, Assistant Chief Executive Officer at KFSHRC, joined the session “Incorporating Healthcare Data & Genomics into AI Models to Identify Rare Diseases,” focusing on leveraging advanced data science and precision medicine to improve early diagnosis and outcomes. Both Dr. Al Banyan and Dr. AlSwailem also served as judges at the Startup Showcase, further reinforcing KFSHRC’s
support for innovation-driven healthcare entrepreneurship.
KFSHRC’s participation signals a new chapter of global engagement, aligning with its mission to advance medical excellence, drive scientific discovery, and elevate the Kingdom’s healthcare sector to world-leading standards. By joining the C3 Davos of Healthcare™ Japan Summit, KFSHRC aims to strengthen global alliances that accelerate innovation and improve health outcomes across borders.
King Faisal Specialist Hospital & Research Centre has been ranked first in the Middle East and Africa and 20th globally, in the list of the world’s top 250 Academic Medical Centres for the second consecutive year and recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. Additionally in the same year, it was ranked among the world's best 250 hospitals by Newsweek magazine.
(KFSHRC) PARTICIPATED IN THE C3 DAVOS OF HEALTHCARE™ JAPAN SUMMIT, THAT TOOK PLACE ON SEPTEMBER 24, 2025 UNDER THE THEME “A TRI-NATION COLLABORATION: BUILDING BRIDGES BEYOND BORDERS IN HEALTHCARE,” BRINGING TOGETHER GLOBAL LEADERS, POLICYMAKERS, INVESTORS, AND INNOVATORS TO FOSTER INTERNATIONAL DIALOGUE AND COLLABORATION.
Committed to sustainable healthcare
The world of health never stands still. And neither have we. At every moment that counts, we will be there.
Improving safety to protect patients and caregivers and expanding access to quality care, to providing healthcare professionals with personalised and timely support all along the patient journey
Our 125 years of experience has enabled strategic partnerships and a broad manufacturing and distribution scale that uniquely positions us as key actors in providing the right care, at the right place, at the right time.
A Connected Care Vision: BD's Strategy for
Healthcare Transformation
Bilal Muhsin, Executive Vice President and President of
Future Connected Care Segment
In a new era of digital transformation, healthcare is rapidly evolving to be more connected, efficient, and patient-centric.
At the forefront of this change is BD, a global leader in MedTech innovation. We recently interviewed Mr. Bilal Muhsin, the Executive Vice President and President of BD's new Connected Care segment, to discuss his new role and his vision for the future of healthcare. In this exclusive interview, Mr. Muhsin shares insights into how BD’s strategic partnerships and innovative solutions are advancing patient safety and shaping the future of medicine, particularly in high-growth regions such as the Middle East.
You recently joined BD as Executive Vice President and President of the Connected Care segment. What inspired you to take on this role, and how do you see your experience helping shape BD’s vision for the future?
I was inspired to join BD after meeting with Tom Polen, BD’s Chairman, CEO, and President, and hearing his compelling vision for the
organization. Having spent over 25 years at Masimo, where I was privileged to lead innovation and growth in patient monitoring and healthcare technologies, I saw a unique opportunity at BD to take that experience to a global scale, impacting even more patients.
BD is at the forefront of MedTech innovation, with a portfolio that touches nearly every aspect of healthcare. My experience in medical engineering, software, and connected technologies aligns well with the company’s strategy to advance digital health, automation, and data-driven solutions. I look forward to contributing my efforts towards shaping BD’s journey as a differentiated, pure-play MedTech leader and to working alongside an exceptional global team committed to transforming healthcare and improving patient outcomes.
Connected Care is a newly created segment at BD. Can you tell us more about what Connected Care encompasses and how its innovations are transforming patient safety, efficiency, and outcomes?
BD IS AT THE FOREFRONT OF MEDTECH INNOVATION, WITH A PORTFOLIO THAT TOUCHES NEARLY EVERY ASPECT OF HEALTHCARE. MY EXPERIENCE IN MEDICAL ENGINEERING, SOFTWARE, AND CONNECTED TECHNOLOGIES ALIGNS WELL WITH THE COMPANY’S STRATEGY TO ADVANCE DIGITAL HEALTH, AUTOMATION, AND DATA-DRIVEN SOLUTIONS.
INTERVIEWS
Connected Care brings together BD’s Medication Management Solutions and Advanced Patient Monitoring businesses, two powerful areas with millions of smart devices in use around the world. By combining them, we are building an ecosystem that leverages automation, AI, and advanced analytics to make healthcare more efficient and more effective.
For example, our medication dispensing technologies and infusion systems are designed to reduce medication errors and ensure critical drugs are available exactly when needed. On the monitoring side, our solutions provide clinicians with real-time insights that improve decisionmaking at the bedside.
I'm particularly excited about our product pipeline and the new connected solutions we have designed to unify our technologies across the continuum of care from pharmacy to bedside and beyond. Our goal is to transform how clinicians interact with data, devices, and each other as we leverage cloud technologies and AI to help break down silos, automate workflows, and deliver predictive insights that improve patient safety and workflow efficiency. These new connected solutions will be a critical part of our strategy and further position BD as a leader in this space.
BD has announced its “New BD” strategy with a clear emphasis on high-growth markets. How does the Middle East fit into this global strategy?
The Middle East region is at the very center of BD’s future growth strategy. Countries like Saudi Arabia and the UAE, alongside other Gulf nations, are undergoing an ambitious healthcare transformation in their efforts to become the most dynamic markets for healthcare innovation worldwide.
For BD, this means investing in a robust manufacturing footprint to better support customers in the region, supporting local talent development, and developing deeper relationships with partners and customers. We have established a regional headquarters in Riyadh, expanded our commercial presence, and opened the BD Training Center earlier this year to equip healthcare professionals with hands-
on training and best practices. The country’s emphasis on innovations like digitalization, valuebased care, and innovation aligns perfectly with BD’s Connected Care vision. We look forward to announcing the strategic partnerships that BD will enter to support healthcare transformation in the Kingdom during the upcoming Global Health Exhibition in Riyadh.
Tell us more about BD’s participation at the upcoming Global Health Exhibition in Riyadh. What can we expect from BD’s presence at the event, and what messages are you hoping to convey to partners, customers, and the wider healthcare community?
The Global Health Exhibition in Saudi Arabia is a landmark event for us, as it brings together policymakers, healthcare leaders, and innovators from across the region. BD will showcase how we are advancing patient safety, efficiency, and healthcare worker protection through our Signature Programmes, our Connected Care portfolio, as well as Medication Delivery, Interventional, and Diagnostic solutions. Visitors to our booth will see how automation, AI, and analytics can be applied to medication management, infusion, and advanced monitoring to improve patient outcomes and optimize healthcare delivery. Just as importantly, we will use this platform to listen and engage with customers, partners, and government leaders to better understand their priorities and explore how BD can support the Kingdom’s healthcare transformation.
During your visit to Saudi Arabia and the region, what are your main priorities on the agenda?
My visit is an opportunity to engage directly with stakeholders across Saudi Arabia’s healthcare ecosystem. This includes meeting with representatives from the Ministry of Health and government, healthcare executives, and strategic partners to discuss how BD can collaborate more closely in advancing national healthcare priorities.
I’m also connecting with our BD teams on the ground, who are driving much of the
THE MIDDLE EAST REGION IS AT THE VERY CENTER OF BD’S FUTURE GROWTH STRATEGY. COUNTRIES LIKE SAUDI ARABIA AND THE UAE, ALONGSIDE OTHER GULF NATIONS, ARE UNDERGOING AN AMBITIOUS HEALTHCARE TRANSFORMATION IN THEIR EFFORTS TO BECOME THE MOST DYNAMIC MARKETS FOR HEALTHCARE INNOVATION WORLDWIDE. FOR BD, THIS MEANS INVESTING IN A ROBUST MANUFACTURING FOOTPRINT TO BETTER SUPPORT CUSTOMERS IN THE REGION, SUPPORTING LOCAL TALENT DEVELOPMENT, AND DEVELOPING DEEPER RELATIONSHIPS WITH PARTNERS AND CUSTOMERS.
impact we make every day to advance the world of health. Saudi Arabia, the United Arab Emirates, and the rest of the Gulf countries are key growth markets for BD globally, and these engagements will help ensure that we are aligned with the countries' visions and can deliver long-term value through innovation, education, and partnerships.
BD has been advancing its Signature Programmes in areas, namely patient safety, healthcare worker protection, and efficiency. How do these initiatives tie into the Connected Care segment and vision?
BD’s Signature Programmes are central to our commitment to sustainable healthcare and advancing healthcare outcomes. These
programmes address some of the most pressing challenges facing hospitals today: medication errors, healthcare-associated infections, rising costs, and the need to improve clinical efficiency.
Through Connected Care, technology is the backbone that makes these programmes actionable. For instance, our connected medication management, monitoring, and dispensing systems operate to reduce preventable harm, while our efficiency-focused solutions streamline workflows to allow healthcare workers to spend more time with patients. In Saudi Arabia, these programmes are already making an impact. Our recent collaboration with the Saudi Patient Safety Center to advance patient safety across almost 500 hospitals is one example of how we are applying global expertise to deliver meaningful local outcomes.
What is your long-term vision for the Connected Care segment globally and regionally? Where do you see the greatest opportunities to make an impact in the coming years?
My long-term vision is for BD Connected Care to become the global leader in helping clinicians move from being reactive to being proactive in saving lives. This means creating solutions that don’t just respond to problems but anticipate and prevent them, through predictive analytics, advanced monitoring and integrated medication management.
I see enormous growth potential in Saudi Arabia and the broader Middle East region. The ambition, investment and appetite for innovation here are unmatched. By working closely with governments, hospitals and partners, we can accelerate digital transformation, elevate clinical standards, and create a more sustainable healthcare ecosystem. Ultimately, our goal is simple but powerful: to empower healthcare professionals with the tools, data, and support they need to deliver safer, smarter, and more efficient care for every patient – and thus advancing the world of health to drive progress in our communities.
BD’S SIGNATURE PROGRAMMES ARE CENTRAL TO OUR COMMITMENT TO SUSTAINABLE HEALTHCARE AND ADVANCING HEALTHCARE OUTCOMES. THESE PROGRAMMES ADDRESS SOME OF THE MOST PRESSING CHALLENGES FACING HOSPITALS TODAY: MEDICATION ERRORS, HEALTHCAREASSOCIATED INFECTIONS, RISING COSTS, AND THE NEED TO IMPROVE CLINICAL EFFICIENCY.
Liquid biopsy in breast cancer – Less invasion more precision
Plasma-SeqSensei™
Liquid biopsy in breast cancer – Less invasion more precision
Plasma-SeqSensei™
The Plasma-SeqSensei Breast Cancer IVD Kit is an NGSbased liquid biopsy assay that focuses on highly sensitive detection of clinically relevant mutations in TP53, ESR1, PIK3CA, AKT1 and ERBB2 from blood plasma.
Learn more about the unique advantages of Plasma-SeqSensei technology
The Plasma-SeqSensei Breast Cancer IVD Kit is an NGSbased liquid biopsy assay that focuses on highly sensitive detection of clinically relevant mutations in TP53, ESR1, PIK3CA, AKT1 and ERBB2 from blood plasma.
High sensitivity at low MAFs
Learn more about the unique advantages of Plasma-SeqSensei technology
Down to 0.06% - 0.07% Mutant Allele Fractions.
High sensitivity at low MAFs
Down to 0.06% - 0.07% Mutant Allele Fractions.
Absolute quantification
Short and standardised workflow
From cfDNA samples to results in two days.
Short and standardised workflow
From cfDNA samples to results in two days.
Data analysis and reporting made easy
Generate report designed for clinicians with just a few clicks.
Absolute quantification
Meaningful comparison of ctDNA levels per millilitre of plasma.
Expert voices
Meaningful comparison of ctDNA levels per millilitre of plasma.
Data analysis and reporting made easy
Generate report designed for clinicians with just a few clicks.
Expert voices
‘We know that tissue samples cannot be taken regularly, but liquid biopsy is easy to take, it is simply a sample of blood. And it gives you real-time information.’
Dr Bhuwnesh Agrawal Member of The Supervisory Board
‘Even low levels of ctDNA could have given an indication of the coming progression in the follow-up.’
‘There is much more diagnostic power in the absolute quantification.’
‘We know that tissue samples cannot be taken regularly, but liquid biopsy is easy to take, it is simply a sample of blood. And it gives you real-time information.’
Sysmex Inostics and MD, Germany
Dr Bhuwnesh Agrawal Member of The Supervisory Board
Sysmex Inostics and MD, Germany
‘Even low levels of ctDNA could have given an indication of the coming progression in the follow-up.’
‘There is much more diagnostic power in the absolute quantification.’
Prof. Christopher Gebhardt UKE Hamburg, Germany
Prof. Christopher Gebhardt UKE Hamburg, Germany
Prof. Geert A. Martens AZ Delta General Hospital, Belgium
Prof. Geert A. Martens AZ Delta General Hospital, Belgium
April 8-11, 2025
Shanghai, China
Sept. 26-29, 2025
Guangzhou, China
Exhibitors
Connecting Care. Building Trust.
For nearly 50 years, Pharmatrade has empowered UAE healthcare with advanced medical devices, lab automation, pharmaceuticals, and nationwide logistics—driving trust, innovation, and excellence in patient care.
Unlocking Access Through Better Coding
Priorities for Medical Devices and In‑Vitro Diagnostics in Saudi Arabia’s Healthcare System
Medical Coding is the silent backbone of modern care and a foundational component of health systems. By translating clinical diagnoses, procedures, and services into standardized alphanumeric codes, medical coding enables the systematic documentation, billing, reimbursement, and analysis of healthcare activities across both public and private sectors1. Beyond its administrative utility, medical coding plays a critical role in shaping national health policy, informing epidemiological research, guiding health technology assessments (HTA), and supporting the implementation of value -based care models2 .
As healthcare systems globally transition toward data-driven decision-making, the accuracy and consistency of coding practices have become integral to ensuring transparency, efficiency, and accountability2
In Saudi Arabia, where healthcare transformation is a strategic pillar of Vision 2030, the development and standardization of medical coding infrastructure are central to achieving national health objectives. Initiatives led by the Saudi Health Council and other
regulatory bodies emphasize the need for robust clinical classification systems, localized coding adaptations, and improved coding literacy among providers.
This article provides an overview of the major challenges and opportunities related to innovative technologies coding in the Kingdom of Saudi Arabia. It highlights critical topics that must be addressed to ensure effective future planning and decision-making, particularly as the Kingdom advances its Vision 2030 healthcare transformation agenda.
These topics include budget-conscious decision-making, timely access to innovative technologies, closing coding gaps, and addressing the rapid pace of medical device innovation. By tackling these issues, the coding framework in the Kingdom can support innovation, enable efficient reimbursement, and enhance patient access to high-value medical technologies. Additionally, this article highlights the pivotal role of the medical technology industry in shaping solutions. Through advocacy, collaboration, and training, Mecomed can help build robust coding frameworks that support innovation, reimbursement, and patient access.
IN SAUDI ARABIA, WHERE HEALTHCARE TRANSFORMATION IS A STRATEGIC PILLAR OF VISION 2030, THE DEVELOPMENT AND STANDARDIZATION OF MEDICAL CODING INFRASTRUCTURE ARE CENTRAL TO ACHIEVING NATIONAL HEALTH OBJECTIVES. INITIATIVES LED BY THE SAUDI HEALTH COUNCIL AND OTHER REGULATORY BODIES EMPHASIZE THE NEED FOR ROBUST CLINICAL CLASSIFICATION SYSTEMS, LOCALIZED CODING ADAPTATIONS, AND IMPROVED CODING LITERACY AMONG PROVIDERS.
Key Concerns & Considerations
Budget‑Conscious Decision‑Making
Worldwide, healthcare expenditures are rising and Saudi is no exception, and payers are expected to explore different mechanisms of reducing costs. This can lead to internal policies that restrict the adoption of the best medical technologies, even when they offer long-term value or improved patient outcomes.
Access to Innovative Technologies
Many cutting-edge medical devices are not adequately captured under Australian Refined Diagnosis Related Group (AR-DRG v9). Without appropriate coding, hospitals may default to lower-cost, less effective solutions, limiting patient access to the best available care.
Devices Innovation Pace
The innovation cycle of medical devices is very fast. On average, manufacturers introduce a new version or significant upgrade to existing devices every three years. These updates can range from minor design refinements to major technological breakthroughs. This rapid cycle creates challenges for reimbursement and coding systems, which are typically updated less frequently. As a result, new versions may enter clinical practice without appropriate coding or funding, slowing adoption and limiting patient access to the latest, most effective technologies.
Short‑Term Focus in Decision‑Making
Healthcare decisions, especially in budgeting and coding, often prioritize short-term cost containment over long-term value and outcomes. This can disadvantage innovative therapies that may have higher upfront costs but offer substantial savings and health benefits over time.
Coding Gaps Hindering Adoption
New innovations or newer versions are often not captured by current procedural or diagnostic codes. It is unclear if innovative technologies or newer versions have been considered in the currently adopted procedural
and diagnostic code sets in KSA. If newer innovations are not captured, providers will be incentivized against adopting these procedures, in favor of traditional medical care, despite any differences in clinical efficacy or the patient experience. On the other hand, establishing new codes is typically a multi-step process involving clinical evidence generation, cost-impact assessment, and stakeholder consultation. During this time, hospitals may be unable to claim appropriate reimbursement, creating financial disincentives to adopt the therapy. Ultimately, this delay can restrict timely patient access to high-value innovations, slow clinical uptake, and limit the health system’s ability to realize potential efficiency and outcomes gains.
Role of Mecomed & MedTech Industry
The medical technology industry, represented by organizations like Mecomed, plays a pivotal role in advancing better coding practices. Proper coding benefits both industry (ensuring access and reimbursement) and the health system (enhancing transparency and efficiency). In Saudi Arabia, Mecomed can act as both advocate and solution partner, uniting stakeholders (manufacturers, distributors, providers, and regulators) to drive coding improvements that support innovation and access.
Advocacy & Expertise
Mecomed bridges the best global practices and local implementation, advocating for international coding standards and highlighting success stories. Its KSA Chapter actively promotes the best practices in MedTech policy, with coding as a key focus.
Technical Collaboration
Industry can support code development by providing clinical data for new devices, similar to how manufacturers engage with coding bodies like CMS in the U.S.; local Mecomed members can assist Saudi regulators in updating code libraries and forecasting coding needs via structured collaboration.
Training and Capacity Building
Mecomed can support coder training in
NEW INNOVATIONS OR NEWER VERSIONS ARE OFTEN NOT CAPTURED BY CURRENT PROCEDURAL OR DIAGNOSTIC CODES. IT IS UNCLEAR IF INNOVATIVE TECHNOLOGIES OR NEWER VERSIONS HAVE BEEN CONSIDERED IN THE CURRENTLY ADOPTED PROCEDURAL AND DIAGNOSTIC CODE SETS IN KSA. IF NEWER INNOVATIONS ARE NOT CAPTURED, PROVIDERS WILL BE INCENTIVIZED AGAINST ADOPTING THESE PROCEDURES, IN FAVOR OF TRADITIONAL MEDICAL CARE, DESPITE ANY DIFFERENCES IN CLINICAL EFFICACY OR THE PATIENT EXPERIENCE.
device-heavy specialties, through workshops and webinars. This builds local expertise, reduces coding errors, and increases provider confidence in adopting new technologies.
Recommendations
• Horizon scanning processes that industry can feed into enable early identification of DRGs that may not sufficiently cover innovative technologies.
• Early multi-stakeholder engagement (payers, coding authorities, clinicians, industry) to anticipate coding needs for emerging innovations.
• Early engagement with industry to map innovative technologies to procedures to DRG codes aiming to identify DRGs that do not sufficiently cover the cost of care from the provider perspective.
• The establishment of mechanisms that maintain financial incentives for providers to use innovative technologies or upgrades to existing technologies, especially for those products that fall out of the scope of HTA. Approaches used worldwide include:
1. Protected budgets for innovative
technologies at the provider level.
2. Allowing interim or provisional codes while full AR-DRG updates are pending, preventing delays in reimbursement.
3. High-cost device list at the payer level that provides top-up reimbursement for approved technologies.
4. Device-level DRG modifiers that enhance the value of a DRG to ensure the innovative technology is covered.
5. Establish fast-tracked pathways for new technologies with strong clinical and economic evidence.
6. Both short and long-term impact of therapies are recommended to be evaluated and considered for decisionmaking and reimbursement.
By adopting the recommendations outlined, from regular updates to stronger stakeholder partnerships, Saudi Arabia can rapidly advance into a future where every medical device and procedure is tracked and valued. The payoff will be seen in the sustainability of healthcare financing, improvement of the health outcomes, and better quality of life of the Saudi population.
References
1. WHO. ICD-11: International Classification of Diseases 11th Revision. 2019. Available from: https:// icd.who.int/en/ 2. Improving Health System Efficiency: The Role of Information and Communication Technologies. 2020.
Contributions & Acknowledgement
• Sarah AlHathlool, PharmD, MSc, Sr. Health Economist
• Martyna Giedrojc-Amir, MPH, Director Value & Access MENA
• Murtada Alsaif, PhD, Health Economics and Market Access Lead
Mecomed is the medical devices, imaging and diagnostics trade association serving as the voice of the Medical Technology industry across the Middle East & Africa. Mecomed aims to bring all healthcare stakeholders together to improve the quality of people’s health through the timely introduction of meaningful Medical Technology innovations, which ultimately benefits the MEA region community. We foster Good Citizenship and promote ethical business behavior, working proactively with governments, regional bodies and healthcare professionals to deliver high‑value solutions for better patient outcomes.
Our Industry Members 2025
Our Associate Members 2025
Advanced Healthcare Infrastructure
The Foundation of Quality, Efficiency, and Patient Safety
Healthcare infrastructure forms the backbone of high-quality medical care, supporting everything from routine patient services to emergency response and medical innovation. Proper management of these resources is critical for operational efficiency, cost control, and most importantly, improved patient outcomes. Modern infrastructure in healthcare facilities and hospitals is a vital investment with a direct impact on care quality, individual safety, operational effectiveness, and the system’s capacity to face future challenges.
Enhancing Patient Care
Real-time tracking systems enable quicker access to essential medical devices, minimizing delays in critical situations and improving treatment outcomes. Preventive and routine maintenance ensures that equipment remains operational, reducing unexpected downtimes and guaranteeing constant diagnostic and treatment readiness. Infrastructure improvements streamline workflows and automate inventory management, allowing healthcare staff to focus more on patient care. Identifying and redistributing underutilized assets helps avoid unnecessary purchases and ensures continuous availability of required medical resources.
Key Benefits of Modern Hospital Infrastructure
Improving Healthcare Quality
Access to cutting-edge technologies such as precision imaging, robotic surgery, and advanced monitoring systems enhances diagnostic accuracy, treatment effectiveness, and reduces complications. Modern facility design supports therapeutic recovery through calm, welllit, ventilated, and quiet spaces that reduce patient stress. Updated layouts improve patient navigation, offer mobility-friendly access, and
ensure practical parking and accommodation for individuals with special needs.
Ensuring Safety
Advanced ventilation systems, easy-to-clean materials, and hygienic designs help prevent the spread of infections. Buildings constructed to rigorous engineering standards protect patients and staff during emergencies like earthquakes or fires. Well-designed, ergonomic workspaces reduce physical strain on healthcare professionals, minimizing injury and fatigue.
Boosting Operational Performance
Efficient layouts and improved departmental integration speed up workflows and service delivery. Smart systems for managing energy, water, and supplies lower utility costs and contribute to sustainability goals. Integrated electronic health records and hospital information systems simplify administrative duties and improve coordination between medical teams.
Emergency Preparedness
Resilient infrastructure increases capacity to manage sudden patient influxes during epidemics or disasters. Flexible design enables hospitals to quickly adjust operations and services in crisis situations.
What Constitutes Healthcare Infrastructure
Healthcare infrastructure includes the systems, resources, and frameworks that support medical service delivery. This encompasses a variety of key elements: Medical facilities such as hospitals, clinics, rehabilitation centers, nursing homes, and long-term care institutions provide the necessary environments for diagnosis, treatment, and patient recovery. Medical equipment and technologies include diagnostic tools like CT scanners and X-rays, treatment devices, surgical instruments,
PREVENTIVE AND ROUTINE MAINTENANCE ENSURES THAT EQUIPMENT REMAINS OPERATIONAL, REDUCING UNEXPECTED DOWNTIMES AND GUARANTEEING CONSTANT DIAGNOSTIC AND TREATMENT READINESS. INFRASTRUCTURE IMPROVEMENTS STREAMLINE WORKFLOWS AND AUTOMATE INVENTORY MANAGEMENT, ALLOWING HEALTHCARE STAFF TO FOCUS MORE ON PATIENT CARE.
and platforms for electronic health records and telemedicine. The healthcare workforce comprises physicians, nurses, pharmacists, technicians, and administrative staff who are essential to service provision. Supply chain and logistics systems ensure timely access to medicines, supplies, and equipment. Public health systems include epidemiological monitoring, disease prevention programs, and community health promotion. Information technology supports data management, remote monitoring, and communication between healthcare facilities.
Assets in the Healthcare Sector
Healthcare assets consist of physical and digital resources that support daily operations. These include high-tech devices such as ventilators and patient monitors, along with basic tools like wheelchairs, beds, and stretchers. IT
infrastructure includes servers, computers, mobile devices, network hardware, and connected systems that manage data and operations. Facilities include the hospital buildings and essential services like heating, ventilation, plumbing, and electrical systems. Furniture such as beds, chairs, desks, and cabinets supports both clinical and administrative tasks. Medical consumables include frequently used items such as gloves, dressings, and IV bags, which require precise stock management. Pharmaceuticals must be stored and monitored carefully due to their sensitivity, regulatory requirements, and cost. Transportation includes ambulances, patient transfer vehicles, service carts, and maintenance trucks, all of which require proper upkeep. Digital assets consist of management software, electronic records, and other intangible tools critical to modern healthcare operations.
MEDICAL EQUIPMENT AND TECHNOLOGIES INCLUDE DIAGNOSTIC TOOLS LIKE CT SCANNERS AND X-RAYS, TREATMENT DEVICES, SURGICAL INSTRUMENTS, AND PLATFORMS FOR ELECTRONIC HEALTH RECORDS AND TELEMEDICINE.
The Role of Continuous Maintenance
Continuous maintenance is a strategic component of healthcare infrastructure, extending beyond basic repairs to ensure safety, reliability, and long-term efficiency. It allows early detection of faults in systems such as HVAC, lighting, plumbing, and medical gases, preventing service disruptions. Proper maintenance sustains optimal performance of diagnostic and treatment devices, reduces clinical errors, and extends the life of high-cost equipment. Infrastructure upkeep minimizes risks associated with faulty doors, elevators, and flooring, helping prevent workplace injuries. Regular maintenance of ventilation and plumbing systems ensures hygienic environments, reducing the spread of infections. Compliance with local and international safety and health regulations is maintained, protecting institutions from legal risks and reputational damage.
Operational efficiency is significantly enhanced through strategic prevention of costly emergency repairs and by optimizing mechanical systems to effectively reduce energy consumption. Asset tracking plays a crucial role in improving budget planning by accurately identifying future replacement needs, which in turn promotes responsible and sustainable resource allocation. Implementing continuous maintenance routines supports long-term infrastructure development by identifying potential design flaws early and facilitating necessary upgrades before failures occur. This proactive approach allows for the smooth integration of new technologies, ensuring that systems remain current and efficient. Moreover, it contributes significantly to sustainability goals by reducing waste and improving overall energy and material efficiency across the healthcare facility. Viewing maintenance not merely as a cost but as a strategic investment underscores its importance in upholding the quality, safety, and reliability of healthcare services. It is indispensable for any healthcare system aiming to provide consistent, high-quality, and futureready care, ultimately ensuring that patients receive the best possible outcomes in a safe and sustainable environment.
Apex Health Secures Five Prestigious Awards for Patient Experience Excellence from Arab Hospitals Federation
Apex Health, a subsidiary of Estithmar Holding Q.S.P.C. and one of the fastestgrowing healthcare providers in the MENA region, has earned five Distinction Awards under the Arab Hospitals Federation’s Gold Initiative Certificate – Star of Excellence in Patient Experience. The awards underscore the organization’s leadership in delivering patientcentered care across the Middle East.
The recognition was announced during a high-profile ceremony attended by regional healthcare leaders, under the patronage of the Arab Hospitals Federation and in collaboration with The Beryl Institute, a global authority on patient experience. A total of 267 healthcare institutions from 10 countries competed for honors across various categories.
Following a rigorous evaluation by a jury panel in collaboration with The Beryl Institute, Apex Health and four of its hospitals, two in Qatar and two in Iraq, were recognized for excellence in safety, quality, innovation, governance, and the patient journey.
The awards reflect Apex Health’s strategic commitment to clinical excellence, innovation, and a deeply embedded culture of patientcentered care.
“This is a proud moment for our entire team,” said Joseph Hazel, Group CEO of Apex Health. “Earning five certificates of distinction across Qatar and Iraq is a testament to the dedication of our staff, the trust of our patients, and our vision to redefine healthcare standards across the MENA region. Our achievements are built on strong international partnerships and close collaboration with government stakeholders, enabling us to deliver care that is safe, innovative, and personal.”
THE AWARDS REFLECT APEX HEALTH’S STRATEGIC COMMITMENT TO CLINICAL EXCELLENCE, INNOVATION, AND A DEEPLY EMBEDDED CULTURE OF PATIENTCENTERED CARE.
Qatar’s The View Hospital, in affiliation with Cedars-Sinai, earned Gold Awards in Safety and Quality of Care and Continuity of Care & Transition Management
The Military Medical City Hospital, managed by EWS, Qatar, received Silver in Sustainability, Innovation & Technology
Al Imam Al Hassan Al Mujtaba Teaching Hospital, Iraq, awarded Silver in Safety and Quality of Care
Al Nasiriya Teaching Hospital, Iraq, earned Silver in Leadership, Governance, Policy & Culture
Joseph Hazel, Group CEO of Apex Health receiving the Awards
The View Hospital in Affiliation with Cedars-Sinai, Qatar
Military Medical City Hospital - Qatar, Managed by EWS
Hospitals Recognized Across the Region
In Qatar, The View Hospital, in affiliation with Cedars-Sinai, earned Gold Awards in Safety and Quality of Care and Continuity of Care & Transition Management. The dual recognition affirms its commitment to clinical excellence and seamless patient transitions across the care continuum. Also in Qatar, the Military Medical City Hospital, managed by EWS, received Silver in Sustainability, Innovation & Technology, highlighting its progressive adoption of cutting-edge medical solutions and sustainable practices.
In Iraq, Al Imam Al Hassan Al Mujtaba Teaching Hospital in Karbala Governorate was awarded Silver in Safety and Quality of Care, recognizing its adherence to rigorous clinical safety protocols and commitment to delivering reliable, high-quality treatment.
Meanwhile, Al Nasiriya Teaching Hospital in Dhi-Qar Governorate earned Silver in Leadership, Governance, Policy & Culture, underscoring its robust organizational framework and focus on fostering a patient-first culture.
Apex Health also received a Recognition Award under the Gold Initiative Certificate, further cementing its role as a regional leader in trusted, high-quality, and sustainable healthcare delivery.
APEX HEALTH ALSO RECEIVED A RECOGNITION AWARD UNDER THE GOLD INITIATIVE CERTIFICATE, FURTHER CEMENTING ITS ROLE AS A REGIONAL LEADER IN TRUSTED, HIGH-QUALITY, AND SUSTAINABLE HEALTHCARE DELIVERY.
Reinforcing Regional Leadership
The wins come amid the rapid growth of Qatar’s healthcare sector, the surge of private investment and the arrival of internationally renowned medical brands, which are reshaping the landscape not only in Qatar but across the wider Middle East. This shift reflects the transformation from predominantly public provision to a dynamic ecosystem where global affiliations and private providers set new benchmarks for quality and patient care. The prestigious awards position Apex Health at the forefront of healthcare excellence in the Arab world. With a growing portfolio of state-of-the-art medical facilities and a reputation for operational excellence, the group continues to lead transformative changes in the region’s healthcare landscape.
Apex Health’s portfolio includes 8 hospitals across Qatar, Algeria, Iraq and Libya, in affiliation with reputable medical institutions: Cedars Sinai (USA), Asan Medical Center (South Korea),Seoul AHNKANG Hospital (South Korea) and others.
APEX HEALTH’S PORTFOLIO INCLUDES 8 HOSPITALS ACROSS QATAR, ALGERIA, IRAQ AND LIBYA.
Al Imam Al Hassan Al Mujtaba Teaching Hospital - Iraq
Al Nasiriya Teaching Hospital - Iraq
UChicago Medicine emerges as a global leader in focal therapy treatments for prostate cancer
The University of Chicago Medicine’s focal therapy program for prostate cancer has completed more than 300 procedures – a volume that ranks among the highest in the U.S. Focal therapies are new, minimally invasive procedures that target tumors in the prostate. They mark a significant advancement from just a few years ago, when most prostate cancer cases were treated by removing or radiating the entire prostate gland.
The past approaches were “overtreatment” in some cases, said UChicago Medicine urologic oncologist Abhinav Sidana, MBBS, MPH, and often came with unwanted side effects such as urinary incontinence or erectile dysfunction.
With focal therapies, the prostate remains intact, minimizing or eliminating side effects and allowing for faster recovery times. UChicago Medicine is the only hospital in Chicago – and one of just a handful nationwide – to offer the
THE UNIVERSITY OF CHICAGO MEDICINE’S FOCAL THERAPY PROGRAM FOR PROSTATE CANCER HAS COMPLETED MORE THAN 300 PROCEDURES.
Abhinav Sidana, MBBS, MPH, created a comprehensive focal therapy program at the University of Chicago Medicine. The program gives prostate cancer patients every available option for minimally invasive treatments.
full spectrum of focal therapies for prostate cancer. They’re available at UChicago Medicine’s Hyde Park and Tinley Park locations.
“We have a comprehensive focal therapy program,” said Sidana, Director of the Focal Therapy Program. “These treatments help a patient’s quality of life.”
The focal therapies are:
HIFU (high intensity focused ultrasound)
A non-invasive treatment that uses focused sound waves to heat and destroy cancer cells in the prostate without harming surrounding healthy tissue.
IRE (irreversible electroporation)
A precise, non-thermal treatment using electrical pulses to kill cancer cells while preserving nearby nerves and blood vessels –ideal for hard-to-reach areas.
Cryoblation
This method freezes cancer cells using tiny needles and cold temperatures.
TULSA Pro (transurethral ultrasound ablation of the prostate)
A MRI-guided treatment done through the urethra that destroys cancer cells using heat from sound waves.
These treatments are provided through UChicago Medicine’s unique, multidisciplinary focal therapy program that offers each patient a nurse navigator who educates them on the therapy and the process, plus a collaborative team of radiologists, radiation oncologists and urologic oncologists.
Who can have focal therapy for prostate cancer?
Focal therapy isn’t for everyone and it is optional – some patients might opt to remove the prostate altogether and be done with their treatment.
To be eligible for focal therapy, a patient must have an intermediate-risk cancer localized to one side of their prostate.
The team recommends a therapy based on a detailed review of the patient’s imaging, pathology and health history. They also take into account the cancer’s size, location and the patient’s personal preferences.
Since the prostate is not removed with focal therapy, patients will be required to do more follow-up care, and return for regular scans or biopsies to check for cancer recurrences, Sidana said.
Leaders in focal therapy discovery, practice
UChicago Medicine oncologist Scott Eggener, MD, and abdominal radiologist and researcher Aytekin Oto, MD, MBA, pioneered the country’s earliest focal laser ablation trials more than a decade ago. In 2017, Greg Zagaja, MD, now Director of UChicago Medicine’s Prostate Cancer Program, launched one of the initial sites for TULSA-Pro as part of a national clinical trial, leading to its FDA approval.
Building on that research, UChicago Medicine became one of the first hospitals in the country to establish a HIFU program in 2019, led by urologic surgeon Arieh L. Shalhav, MD.
In 2023, Sidana designed the comprehensive focal therapy program, which launched the following year.
In the program’s first 18 months, more than 120 focal therapy procedures have been performed, a milestone that reflects both the technological and innovation in organpreserving prostate cancer care at UChicago Medicine. Sidana has performed more than 350 procedures in the past six years and also trains other doctors from around the world on focal therapies.
Additionally, UChicago Medicine researchers are currently running three clinical trials on focal therapies, one of which involves a new treatment that could soon be available to patients if it receives FDA approval.
Abhinav Sidana, MBBS
Associate Professor of Surgery (Urology) Director of Focal Therapy
Dr. Sidana is a urologic oncologist who specializes in prostate and kidney cancer, performing both robotic and open surgery for patients diagnosed with urologic cancers.
Human bone archive sparks clinical innovation for UCLA Cochlear Implant Program
The program, one of the largest of its kind, offers advanced technology and treatments. People who are profoundly deaf or severely hard of hearing may make the decision to get cochlear implants, surgically implanted electronic devices that receive sounds from an externally worn transmitter. For those patients, the UCLA Cochlear Implant Program offers some of the most advanced technology and treatment in California.
According to Akira Ishiyama, MD, a program director, the strong emphasis on research is what sets UCLA’s program apart, including painstaking study of an archive of human bones.
“The UCLA Human Temporal Bone
Laboratory has one of the largest collections of archival human temporal bones obtained from patients who had cochlear implants,” Dr. Ishiyama says. “We analyze these bones carefully to translate how to perform cochlear implantation to minimize the intracochlear changes from electrode insertion.”
The goal, he says, is to maintain long-term cochlear health. In addition to the archive, ongoing clinical trials ensure that patients have access to the newest technology and procedures.
“I use local anesthesia and sedation (monitored anesthesia care) rather than conventional general anesthesia, particularly in older patients who are afraid to receive general
ACCORDING TO AKIRA ISHIYAMA, MD, A PROGRAM DIRECTOR, THE STRONG EMPHASIS ON RESEARCH IS WHAT SETS UCLA’S PROGRAM APART, INCLUDING PAINSTAKING STUDY OF AN ARCHIVE OF HUMAN BONES.
anesthesia,” says Dr. Ishiyama, who also serves as a professor of otolaryngology in the Department of Head and Neck Surgery and Otology/ Neurotology at the UCLA School of Medicine. “There are only a few centers in the country capable of providing this treatment.”
The surgery is performed on an outpatient basis with the possibility of an overnight stay or a 23-hour observation period. Patients return two to three weeks after surgery for the implant to be activated.
Identifying surgical candidates
According to Dr. Ishiyama, cochlear implantation may be appropriate in pre-lingual children with deafness, post-lingual patients with a short duration of deafness and post-lingual adult patients who are struggling with using hearing aids due to the severity of hearing loss.
Optimal adult candidates for cochlear implants include those who have an anatomically intact auditory nerve, good speech and language skills, and severe to profound hearing impairment in both ears. The families of infants or young children who receive the implant should be willing to help the patient work on
speech and language skills through therapy including the AVT (auditory verbal treatment).
The importance of ongoing care
The program’s full-time cochlear implant coordinator provides patients with comprehensive healthcare support, something that is particularly important for families of infants who are diagnosed with profound hearing loss and older adults who cannot talk on the phone, according to Dr. Ishiyama.
After implantation, audiologists and speech pathologists work with patients to help them develop communication skills and adjust to having cochlear implants.
Receiving an implant can have a profound effect on a patient’s life, Dr. Ishiyama noted.
“Children with congenital deafness can develop age-appropriate speech patterns by the time they are ready to attend a mainstream school,” he said. “Post-lingual adult patients will notice a significant hearing improvement.”
ACCORDING TO DR. ISHIYAMA, COCHLEAR IMPLANTATION MAY BE APPROPRIATE IN PRE-LINGUAL CHILDREN WITH DEAFNESS, POSTLINGUAL PATIENTS WITH A SHORT DURATION OF DEAFNESS AND POST-LINGUAL ADULT PATIENTS WHO ARE STRUGGLING WITH USING HEARING AIDS DUE TO THE SEVERITY OF HEARING LOSS.
For more information, please visit https://www.uclahealth.org/departments/head-neck-surgery/clinical-services/cochlear-implant-program https://www.uclahealth.org/international-services/ or call +1 310-794-8759
A Center Exclusively Focused on Breast Cancer Treatment
Being recognized as a world-class breast cancer clinic is built on medical expertise, continuity of care, and a multidisciplinary approach. At Acıbadem, more than 50 physicians from various specialties, all with dedicated expertise in breast cancer, collaborate to meticulously plan, deliver, and manage every aspect of patient care. Hundreds of patients from around the world choose the Acıbadem Breast Cancer Clinic for their treatment each year.
Each type of cancer is unique and has its own characteristics. Breast cancer is not only the most common cancer in women but also carries symbolic significance related to body image and femininity. That’s why, at Acıbadem, we prioritize preserving the breast’s appearance whenever possible. We perform breast-conserving surgery, which involves removing the tumor along with a safe margin of surrounding healthy tissue, rather than the entire breast.
Staying Motivated is Crucial
A breast cancer diagnosis can be deeply challenging for many women. Prof. Cihan Uras emphasizes the importance of physicians supporting patients throughout their treatment journey: “We must truly understand what the patient is going through. That’s very important. Yes, there is a lesion in the breast, but we can manage this condition successfully. There is no need to be afraid. Staying motivated during treatment is crucial for all of us. I believe strong morale is vital because it boosts the immune system, and the immune system fights cancer cells.”
A Comprehensive Multidisciplinary Approach
A multidisciplinary approach is essential in the treatment of breast cancer. At Acıbadem, all relevant medical specialties come together not only to ensure accurate diagnosis and effective treatment, but also to support every stage of the patient’s healing journey.
Within the clinic, surgeons, medical oncologists, radiologists, radiation oncologists, geneticists, pathologists, plastic surgeons, nurses, psychologists, and dietitians work collaboratively. What makes the Acıbadem Breast Cancer Unit unique is that each expert is specifically trained in and fully dedicated to breast cancer care.
Every week, the team discusses each patient’s case in detail to determine the most appropriate treatment plan. From diagnosis to recovery, the entire process is meticulously planned, carried out, and closely monitored by a highly specialized multidisciplinary team.
A Clinic with a Quarter-Century of Experience
Professor Cihan Uras, one of the pioneers in breast cancer treatment in Türkiye, has led the Acıbadem Breast Cancer Clinic for 25 years. This long-standing experience allows both physicians and patients to navigate the treatment process more smoothly, even with the high patient volume at the center. The clinic serves not only local patients but also attracts individuals from around the world who seek advanced treatment options.
Prof. Uras shares: “It is an honor to care for patients who travel from their home
A MULTIDISCIPLINARY APPROACH IS ESSENTIAL IN THE TREATMENT OF BREAST CANCER. AT ACIBADEM, ALL RELEVANT MEDICAL SPECIALTIES COME TOGETHER NOT ONLY TO ENSURE ACCURATE DIAGNOSIS AND EFFECTIVE TREATMENT, BUT ALSO TO SUPPORT EVERY STAGE OF THE PATIENT’S HEALING JOURNEY.
countries to seek treatment here. Being recognized as a trusted global center reflects the credibility of Türkiye, Acıbadem, and our clinic. Serving international patients is both a great responsibility and a true source of happiness for us. Every patient is unique and like a member of our family. We always aim to do our best for them.”
An Extraordinary Case That Inspires Patients
While some breast cancers can be treated relatively easily, others may require a longer and more complex journey. The story of a young woman treated at Acıbadem shows how meticulous planning and personal determination can lead to life-changing outcomes, offering hope to others facing similar challenges.
Shortly after getting engaged, she was diagnosed with breast cancer. Following screening and biopsy, her treatment plan was designed, beginning with chemotherapy. However, because chemotherapy affects fertility, she was advised to undergo egg or embryo freezing to preserve her chance of becoming a mother in the future before starting treatment. However, according to regulations in Türkiye, only married couples are allowed to freeze embryos. With remarkable determination, the couple made a swift and heartfelt decision to get married. Following their marriage and the successful embryo freezing procedure, she began chemotherapy. This was followed by breast-conserving surgery and radiotherapy, which successfully eliminated the tumor. To help prevent recurrence, she started anti-hormonal therapy in the form of oral medication.
In the third year of treatment, her hormonal therapy was paused. The frozen embryos were used, and, thankfully, pregnancy was achieved. She gave birth to a healthy baby. After delivery, she resumed her hormonal treatment. By the end of her journey, she was married, became a mother, and successfully overcame breast cancer.
Professor Cihan Uras reflects on the case: “This story is one of the most inspiring examples, not only of overcoming disease but
also of taking ownership of one’s future and the will to keep going. Stories like this remind me why I chose this profession.”
Improved Outcomes in Metastatic Breast Cancer
In the past, a diagnosis of metastatic breast cancer came with a very low chance of survival. But today, thanks to advances in chemotherapy, targeted therapies, and immunotherapy, outcomes have significantly improved. Professor Cihan Uras shares another case: “Today, I operated on a patient who was diagnosed with metastatic breast cancer three years ago at our clinic. She had undergone chemotherapy and anti-hormonal therapy. When we re-evaluated her condition, everything looked very good. Only small tumors remained in the breast and axilla, and we removed them. In the past, operating on such patients would have been impossible. But now, everything has changed for the better.”
IN THE PAST, A DIAGNOSIS OF METASTATIC BREAST CANCER CAME WITH A VERY LOW CHANCE OF SURVIVAL. BUT TODAY, THANKS TO ADVANCES IN CHEMOTHERAPY, TARGETED THERAPIES, AND IMMUNOTHERAPY, OUTCOMES HAVE SIGNIFICANTLY IMPROVED.
Professor Cihan Uras
Speech & Language Therapy: Empowering Children with ADHD
Ms. Olfa Fellah, a seasoned speech and language therapist at Al-Ahli Hospital/Qatar
Attention Deficit/Hyperactivity Disorder (ADHD) affects children worldwide, including here in Qatar. While medical management often centers on pharmacology and behavioral therapy, one crucial, and sometimes overlooked, component is speech and language therapy. At Al-Ahli Hospital, Ms. Olfa Fellah, a seasoned speech and language therapist, leads this essential service with proven success.
STUDIES SHOW THAT ADHD PREVALENCE IN QATAR ALIGNS WITH GLOBAL AVERAGES, APPROXIMATELY 8–9% OF SCHOOL-AGE CHILDREN.
Understanding ADHD in Qatar
Studies show that ADHD prevalence in Qatar aligns with global averages, approximately 8–9% of school-age children. A cross-sectional survey of independent and private schools revealed that 8.3% of students aged 6–19 exhibited ADHD symptoms, with boys showing higher rates: 16.4% for ages 6–9 and 12.3% for ages 10–12, compared to 4.1% and 6.1% in girls, respectively. This aligns with regional figures
from the Middle East, where prevalence ranges between 7.8–11.1%. Local institutions like HMC and Sidra Medicine offer dedicated Child & Adolescent Mental Health Services (CAMHS), complemented by the Qatar ADHD Support Group established in 2008. They provide comprehensive assessment, parent–teacher training, and multidisciplinary support.
Why ADHD is Rising and Why It Matters
Globally, ADHD is driven by a combination of genetic predisposition, prenatal factors (such as tobacco or substance exposure), and early childhood environmental influences. In Qatar, lifestyle changes, including increased screen time, urban living, and stress, may also exacerbate symptoms among vulnerable children. The impact is significant: ADHD can impair academic performance, social interactions, and emotional well-being. Untreated ADHD in adolescents may even elevate the risk of traffic accidents, injury, and psychiatric comorbidities.
The Role of Speech and Language Therapy
Although ADHD is not a primary speech disorder, many children struggle with language processing, social communication, working memory, and executive functioning. Speech therapy supports these areas by:
• Enhancing expressive and receptive language skills
• Improving organization and clarity of speech, supporting academic literacy
• Promoting social communication skills, vital for peer and classroom interaction
• Providing strategies for memory, focus, and task sequencing
At Al-Ahli Hospital, the Speech & Language Therapy Unit, integrated with the Pediatrics Department, offers advanced diagnostic and intervention services for these challenges.
Spotlight: Ms Olfa Fellah, Leader in Therapy Excellence
Ms. Olfa Fellah is a licensed Speech & Language
Therapist (QCHP license A18924) with over 15 years of experience spanning Tunisia, France (Paris), and London. Fluent in Arabic, English, and French, she brings a multicultural perspective essential for Qatar’s diverse population.
At Al-Ahli Hospital, she offers:
• Individualized therapy plans tailored to each child’s unique ADHD profile
• Parental coaching sessions, equipping caregivers with strategies to support language development at home
• Collaboration with pediatricians, psychologists, and educators for a holistic approach
• Continuous quality improvement, bolstered by Al-Ahli's accreditation and guestcentered care ethos
Parents report marked improvements in their children’s clarity of expression, confidence in school, and participation in social settings.
Al-Ahli's Strengths in ADHD Management
Integrated Multidisciplinary Team
Al-Ahli Hospital enlists over 1,750 clinicians across 30+ specialties. For ADHD, this includes pediatricians, child psychiatrists, psychologists, and Ms. Fellah’s speech team, delivering coordinated care under one roof.
Evidence-Based & Personalized Care
Therapy sessions are based on rigorous assessment protocols, standardized tools, parental and teacher input, to tailor goals and track progress.
World-Class, Guest-Centered Environment
Al-Ahli’s five-star facilities provide comfort and privacy for therapy sessions. Their accreditation in professional education underscores a commitment to ongoing staff training and excellence.
GLOBALLY, ADHD IS DRIVEN BY A COMBINATION OF GENETIC PREDISPOSITION, PRENATAL FACTORS (SUCH AS TOBACCO OR SUBSTANCE EXPOSURE), AND EARLY CHILDHOOD ENVIRONMENTAL INFLUENCES IN QATAR, LIFESTYLE CHANGES, INCLUDING INCREASED SCREEN TIME, URBAN LIVING, AND STRESS, MAY ALSO EXACERBATE SYMPTOMS AMONG VULNERABLE CHILDREN. THE IMPACT IS SIGNIFICANT: ADHD CAN IMPAIR ACADEMIC PERFORMANCE, SOCIAL INTERACTIONS, AND EMOTIONAL WELL-BEING. UNTREATED ADHD IN ADOLESCENTS MAY EVEN ELEVATE THE RISK OF TRAFFIC ACCIDENTS, INJURY, AND PSYCHIATRIC COMORBIDITIES.
Cultural & Linguistic Adaptability
With its multicultural staff, including Ms. Fellah, the hospital supports therapy in Arabic, English, and French.
Treatment Strategies & Best Practices in Qatar
Combining global guidelines with local initiatives, ADHD treatment in Qatar incorporates:
1. Early Detection: Through school screening clinics and CAMHS
2. Pharmacotherapy: Stimulants like methylphenidate or atomoxetine remain first line for moderate to severe cases
3. Behavioral & Psychosocial Therapy: Includes CBT, parent training, and school coordination
4. Speech & Language Intervention: Tailored to ADHD-related language, executive, and social difficulties
5. Ongoing Monitoring: Regular follow-up includes therapy progress, medication reviews, and school feedback
6. Family & School Engagement: Qatar ADHD Support Group and CAMHS foster training and community awareness
Recommendations for Parents and Guardians
• Seek early evaluation, especially if your child shows persistent difficulties in speaking, listening, organizing thoughts, or socializing
• Choose centres offering multidisciplinary care, including speech therapy
• Engage actively in sessions and implement strategies at home
• Monitor progress holistically, not just academic grades, but also language fluency and confidence
The Road Ahead for Qatar
Qatar’s healthcare infrastructure has advanced significantly, with robust CAMHS and innovative efforts by institutions like Al-Ahli. However, challenges remain, including continuing investment in school services, training more specialists, and reducing stigma. Al-Ahli contributes through:
• Professional development programs for
speech therapists
• Collaborative partnerships with schools and HMC
• Enhanced study and tracking of outcomes in speech therapy for ADHD
In Focus: Spotlight Story
A case study (anonymized)
Seven-year-old Zayd, diagnosed with ADHD, struggled with organizing his speech and understanding instructions. Through weekly speech and language therapy with Ms. Fellah, integrated with behavior strategies and medication, he progressed from fragmented sentences to coherent storytelling, improved classroom participation, and increased selfesteem. Ongoing feedback from his parents and teachers confirmed both academic gains and social advancement.
Conclusion
Speech and language therapy is a vital, and often under-recognized, pillar in holistic ADHD care. At Al-Ahli Hospital, Ms. Olfa Fellah combines clinical excellence with compassion, delivering tailored support that empowers children to speak clearly, think coherently, and interact confidently. Backed by Qatar's rising focus on comprehensive mental health, this approach is reshaping outcomes for children with ADHD across the country.
Sidebar: Quick ADHD Facts in Qatar
Indicator Data
ADHD symptoms (ages 6–19)
Boys (6–9)
Boys (10–12)
Girls (6–9)
Girls (10–12)
(Based on studies in Qatari independent & private schools)
www.ahlihospital.com
SPEECH AND LANGUAGE THERAPY IS A VITAL, AND OFTEN UNDER-RECOGNIZED, PILLAR IN HOLISTIC ADHD CARE. AT AL-AHLI HOSPITAL, MS. OLFA FELLAH COMBINES CLINICAL EXCELLENCE WITH COMPASSION, DELIVERING TAILORED SUPPORT THAT EMPOWERS CHILDREN TO SPEAK CLEARLY, THINK COHERENTLY, AND INTERACT CONFIDENTLY. BACKED BY QATAR'S RISING FOCUS ON COMPREHENSIVE MENTAL HEALTH, THIS APPROACH IS RESHAPING OUTCOMES FOR CHILDREN WITH ADHD ACROSS THE COUNTRY.
Empowering Women in the Fight Against Breast Cancer
Equipping women with comprehensive knowledge and practical tools is essential for strengthening early detection and prevention of breast cancer. Empowerment through education and improved access to screening is one of the most effective strategies to reduce breast cancer mortality. When awareness is seamlessly woven into daily life and community settings, it moves beyond information-sharing to drive meaningful and lasting change.
When women are informed about how to perform breast self-exams and are familiar with a wide range of symptoms, including subtle changes in breast texture, shape, or nipple discharge, the likelihood of early diagnosis increases significantly, leading to better health outcomes. A key component of empowerment is dispelling common myths. Misconceptions— such as the belief that only older women are at risk, or that underwire bras cause cancer— often discourage women from taking their health seriously. Replacing these myths with accurate information empowers women to make proactive, informed choices about their well-being.
Social factors also play an important role. Research consistently shows that women’s empowerment, measured through higher levels of education, financial independence, and personal autonomy, is directly linked to greater participation in regular cancer screening programs. When women have control over their lives and access to resources, they are more likely to prioritize their health. By addressing knowledge gaps and correcting societal misconceptions, while simultaneously supporting women’s empowerment, we can adopt a more proactive and effective approach to breast cancer awareness and prevention worldwide. To make a tangible impact, collaboration is key. Partnering with hospitals and NGOs to organize free screening campaigns and workshops can facilitate access to care. Leveraging digital platforms to share
simple, easy-to-understand content about early warning signs and self-examination steps is equally powerful, especially given the growing reach of social media. Using engaging, shareable content to debunk myths equips women with reliable information to guide better health decisions. Highlighting locations that offer free or subsidized mammograms also helps ensure women can access screening services with ease.
Finally, tracking outcomes, such as workshop participation, screening numbers, and community feedback, is crucial for improving future awareness efforts.
Key Aspects of Women’s Empowerment
Strengthening awareness, encouraging early detection, and ensuring access to comprehensive care enable women to take control of their health and improve breast cancer outcomes. Early detection saves lives, and empowering women with knowledge and resources is at the heart of this mission.
Education and Awareness
Expanding knowledge about breast cancer is fundamental. Every woman should understand risk factors, such as family history and lifestyle, as well as the wide range of possible symptoms. These signs extend beyond palpable lumps to include subtle changes such as skin dimpling, puckering, alterations in breast size or shape, and unusual nipple discharge. Awareness campaigns, particularly those during Breast Cancer Awareness Month each October, aim to inspire women to change daily behaviors and actively participate in screening programs.
Self-Examination and Clinical Breast Exams
Breast self-examination empowers women to directly monitor their health. By regularly performing self-checks, women become familiar with their own breast tissue and are better able
WHEN WOMEN ARE INFORMED ABOUT HOW TO PERFORM BREAST SELF-EXAMS AND ARE FAMILIAR WITH A WIDE RANGE OF SYMPTOMS, INCLUDING SUBTLE CHANGES IN BREAST TEXTURE, SHAPE, OR NIPPLE DISCHARGE, THE LIKELIHOOD OF EARLY DIAGNOSIS INCREASES SIGNIFICANTLY, LEADING TO BETTER HEALTH OUTCOMES. A KEY COMPONENT OF EMPOWERMENT IS DISPELLING COMMON MYTHS. MISCONCEPTIONS, SUCH AS THE BELIEF THAT ONLY OLDER WOMEN ARE AT RISK, OR THAT UNDERWIRE BRAS CAUSE CANCER, OFTEN DISCOURAGE WOMEN FROM TAKING THEIR HEALTH SERIOUSLY.
to detect abnormalities early. Self-examination should be followed by clinical breast exams conducted by healthcare providers. Doctors recommend a clinical breast exam at least once every three years for women aged 20–39, and annually for women over 40, to ensure timely detection of any concerns.
Mammography
Mammography is an indispensable diagnostic tool for early detection. It produces highly detailed images capable of identifying tumors too small to be felt. Mammography remains the most effective method for reducing breast cancer mortality. All women are advised to begin regular mammograms at age 40. For those with additional risk factors, such as a strong family history, screening may need to start earlier under medical guidance.
Healthy Lifestyle Choices
Lifestyle plays a preventive role in reducing breast cancer risk. Protective habits include:
• Following a diet rich in fruits, vegetables, and whole grains.
• Engaging in at least 30 minutes of daily physical activity.
• Limiting alcohol intake and avoiding smoking.
• Considering breastfeeding, which research shows may reduce breast cancer risk.
These measures form an essential part of a holistic prevention strategy.
Support and Resources
Global and local organizations, including the World Health Organization (WHO) and the Union for International Cancer Control (UICC, provide comprehensive support programs to ensure timely screening and access to treatment. These programs go beyond medical care, offering psychological and social support to help women navigate the challenges of diagnosis and treatment. Particular focus is placed on improving access in resource-limited settings, where delayed diagnosis remains a primary driver of high mortality rates.
Global Initiatives
International initiatives bring hope for reducing the burden of breast cancer. The WHO’s Global Breast Cancer Initiative, for example, aims to reduce breast cancer mortality by 2.5% annually by 2040. Its framework rests on three pillars: prevention, timely diagnosis, and effective treatment and management.
To achieve these goals, WHO has developed educational resources, including advocacy toolkits and online training courses, to equip stakeholders worldwide with the tools to enhance their efforts in combating breast cancer.
INTERNATIONAL INITIATIVES BRING HOPE FOR REDUCING THE BURDEN OF BREAST CANCER. THE WHO’S GLOBAL BREAST CANCER INITIATIVE, FOR EXAMPLE, AIMS TO REDUCE BREAST CANCER MORTALITY BY 2.5% ANNUALLY BY 2040. ITS FRAMEWORK RESTS ON THREE PILLARS: PREVENTION, TIMELY DIAGNOSIS, AND EFFECTIVE TREATMENT AND MANAGEMENT.
Ovarian Cancer: Advancing Care Through Innovation and Precision
Medicine
Miriana Hijaz, MD FACOG FACS, Division Director of Gynecologic Oncology | Women's Health Services, Henry Ford Health
Clinical Associate Professor | Michigan State University, College of Human Medicine | Henry Ford Cancer Institute, Detroit, MI
Ovarian cancer remains a major challenge in women’s health, often detected late and requiring complex care. Yet, advances in molecular profiling, targeted therapies, and early detection tools are changing the outlook for patients worldwide. "Hospitals" Magazine spoke with Miriana Hijaz, MD, FACOG, FACS, Division Director of Gynecologic Oncology at Henry Ford Health, to discuss the latest breakthroughs, personalized treatment strategies, and the future of ovarian cancer management.
SETTING THE SCENE
How has our understanding of ovarian cancer’s biology evolved in recent years, and what key discoveries are shaping new approaches to the disease?
Over the past several years, the field of oncology has witnessed remarkable advances, and ovarian cancer biology has been at the forefront of this progress. Where ovarian cancer was once regarded as a largely uniform diagnosis with limited therapeutic options, we now understand it as a heterogeneous disease with distinct molecular subtypes. Increasingly, treatment is guided not by a one-size-fitsall approach, but by the unique biological signature of each tumor. Advances in molecular profiling have identified actionable pathways that open the door to immunotherapies, antiangiogenic agents, targeted agents and novel combination regimens. These insights have not only expanded the treatment armamentarium available to patients but have also allowed clinicians to tailor therapies in ways that maximize efficacy while minimizing unnecessary toxicities. In essence, ovarian cancer care is shifting from a generalized framework toward a personalized medicine paradigm.
THE ONGOING CHALLENGE OF EARLY DETECTION
What are the most significant challenges that still prevent early diagnosis, despite advancements in
ADVANCES IN MOLECULAR PROFILING HAVE IDENTIFIED ACTIONABLE PATHWAYS THAT OPEN THE DOOR TO IMMUNOTHERAPIES, ANTI-ANGIOGENIC AGENTS, TARGETED AGENTS AND NOVEL COMBINATION REGIMENS. THESE INSIGHTS HAVE NOT ONLY EXPANDED THE TREATMENT ARMAMENTARIUM AVAILABLE TO PATIENTS BUT HAVE ALSO ALLOWED CLINICIANS TO TAILOR THERAPIES IN WAYS THAT MAXIMIZE EFFICACY WHILE MINIMIZING UNNECESSARY TOXICITIES.
INTERVIEWS
imaging and biomarker research?
One of the greatest challenges in detecting ovarian cancer early is that the disease often develops silently, with vague or nonspecific symptoms that can be mistaken for common benign conditions. Despite progress in imaging and biomarker research, no screening tool has yet proven reliable enough for widespread use, largely because the disease is biologically diverse and early-stage tumors shed very few detectable signals. This combination of subtle symptoms, lack of highly sensitive and specific markers, and tumor heterogeneity continues to make early diagnosis difficult.
Are there any promising developments in screening protocols or diagnostic tools that could realistically shift detection toward earlier stages?
Yes, there are several promising avenues. We have recently seen the development of liquid biopsy technologies, which analyze tumor DNA or other cancer-related signals in the blood. These technologies hold great potential for earlier and less invasive detection. In parallel, researchers are refining multimodal approaches that combine biomarkers with advanced imaging and several risk-stratification algorithms, aiming to identify women at the highest risk more accurately. While these tools are not yet ready for routine screening, they represent important steps toward shifting ovarian cancer diagnosis to earlier, more treatable stages.
How might artificial intelligence and molecular profiling work together to improve early detection and treatment planning?
Molecular profiling now allows us to generate a detailed map of a tumor’s genetic and biological landscape, identifying the key mutations and pathways that drive disease. When paired with artificial intelligence, this information becomes even more powerful. AI algorithms can integrate molecular data with clinical and imaging findings, sometimes even helping to determine the origin of tumors that were previously difficult to differentiate.
Just as importantly, AI can assist in
predicting which therapies are most likely to benefit specific patients, making treatment more precise and effective. This synergy between molecular profiling and AI is moving us closer to a truly personalized approach, one in which each woman’s ovarian cancer can be diagnosed earlier and treated according to the unique biology of her tumor.
BREAKTHROUGHS IN TREATMENT
What breakthroughs in targeted therapy or immunotherapy have had the greatest impact on patient survival in the past five years?
In the past five years, ovarian cancer treatment has seen remarkable progress. PARP inhibitors, especially for patients with BRCA mutations or DNA repair deficiencies, have significantly extended progression-free survival. Targeted therapies like antibody-drug conjugates, have been developed to deliver chemotherapy directly to tumor cells, improving effectiveness while reducing side effects. On the immunotherapy side, we’re learning that certain genetic mutations, can predict better responses to those therapies and can sometimes be added to combination treatments to improve progression-free survival. Exciting experimental approaches, including ovarian cancer vaccines and adoptive cell therapies, are also emerging, pointing toward a future where treatments are increasingly personalized and more effective.
How has the use of PARP inhibitors evolved, and in which patient populations are they showing the most benefit today?
The role of PARP inhibitors in ovarian cancer has expanded significantly, offering substantial benefits to a broader range of patients. Initially, these therapies were primarily used in patients with BRCA1 or BRCA2 mutations. However, recent studies have demonstrated that PARP inhibitors also provide clinical benefits to patients with homologous recombination deficiency (HRD), regardless of BRCA status. Currently, PARP inhibitors are most beneficial as a maintenance therapy following first-line chemotherapy for patients with newly
AI CAN ASSIST IN PREDICTING WHICH THERAPIES ARE MOST LIKELY TO BENEFIT SPECIFIC PATIENTS, MAKING TREATMENT MORE PRECISE AND EFFECTIVE. THIS SYNERGY BETWEEN MOLECULAR PROFILING AND AI IS MOVING US CLOSER TO A TRULY PERSONALIZED APPROACH, ONE IN WHICH EACH WOMAN’S OVARIAN CANCER CAN BE DIAGNOSED EARLIER AND TREATED ACCORDING TO THE UNIQUE BIOLOGY OF HER TUMOR.
diagnosed advanced ovarian cancer who have HRD-positive tumors, including those with BRCA mutations. These patients experience significant improvements in their progressionfree survival. Additionally, patients with platinum-sensitive recurrent ovarian cancer, with BRCA mutations, also benefit from PARP inhibitors, achieving prolonged progressionfree survival. Ongoing research is aiming to further refine patient selection and explore combination therapies to enhance the efficacy of PARP inhibitors in ovarian cancer treatment.
How is genetic testing for BRCA1/2 and other mutations shaping personalized treatment strategies for ovarian cancer? Testing for BRCA and other mutations has now become a central component of ovarian cancer treatment. Not only does it help guide therapies, but it also plays a big role in stratifying patients for various targeted therapies and clinical trials. In addition, and beyond treatment, testing informs risk-reducing strategies for patients and their families, making
it a cornerstone of truly personalized ovarian cancer management.
Can liquid biopsies or circulating tumor DNA analysis meaningfully change how we monitor treatment response and recurrence risk?
Although Liquid biopsies and circulating tumor DNA (ctDNA) analysis are not yet standard of care in ovarian cancer, but emerging studies show real promise. ctDNA can detect molecular signs of recurrence earlier than imaging or symptoms, offering a window for timely intervention. It is also being explored to guide the duration of therapies, helping tailor treatment length to individual disease dynamics and potentially improving both outcomes and quality of life.
SURGICAL APPROACHES AND CARE STRATEGIES
Has the role of surgery in ovarian cancer management changed with the advent of
TESTING FOR BRCA AND OTHER MUTATIONS HAS NOW BECOME A CENTRAL COMPONENT OF OVARIAN CANCER TREATMENT. NOT ONLY DOES IT HELP GUIDE THERAPIES, BUT IT ALSO PLAYS A BIG ROLE IN STRATIFYING PATIENTS FOR VARIOUS TARGETED THERAPIES AND CLINICAL TRIALS
more effective systemic therapies?
Despite advances in systemic therapies, surgery remains a cornerstone of ovarian cancer management. Research has shown that patients who are optimally cytoreduced, especially to no visible residual disease consistently achieve the best survival outcomes. Thus, while systemic treatments continue to evolve, maximal surgical effort remains critical to improving prognosis.
LIFE BEYOND TREATMENT
With survival improving for some patients, how is the focus shifting toward long-term quality of life, fertility preservation, and psychosocial support?
Indeed, survival is improving for many women with ovarian cancer, and now the focus is increasingly shifting toward survivorship and long-term quality of life. Dedicated survivorship can offer multidisciplinary care that extends beyond cancer control. These teams often include reproductive endocrinologists for fertility preservation, psychologists and social workers for emotional and social support, and specialists in menopause and sexual health to manage treatment-related effects. This holistic approach ensures that care is not only lifeprolonging but also life-enhancing.
GLOBAL & FUTURE PERSPECTIVES
How do disparities in healthcare access impact ovarian cancer outcomes globally, and what strategies could bridge this gap?
INTERVIEWS
Disparities in healthcare access profoundly affect ovarian cancer outcomes. Women in lowresource settings often face delayed diagnosis, limited access to surgery or high-volume surgical centers, and scarce availability of targeted therapies or clinical trials.
Bridging this gap requires expanding global access to services like genetic testing, affordable treatments, and surgical expertise, alongside strengthening healthcare infrastructure and training. International collaborations and equitable clinical trial enrollment are also key to ensuring advances in ovarian cancer care benefit women everywhere.
Which emerging technologies or research areas do you believe will define the next decade of ovarian cancer management? I believe the future lies within more personalized and precision-based medicine, with technologies aiming at early detection, fighting therapy resistance, being able to monitor treatment outcomes in real-time, as well as AI-powered precision profiling that can match patients to the therapies most likely to work. We aim for knowledge and expertise that will ensure women don’t just live longer, but live better.
I BELIEVE THE FUTURE LIES WITHIN MORE PERSONALIZED AND PRECISION-BASED MEDICINE, WITH TECHNOLOGIES AIMING AT EARLY DETECTION, FIGHTING THERAPY RESISTANCE, BEING ABLE TO MONITOR TREATMENT OUTCOMES IN REALTIME, AS WELL AS AIPOWERED PRECISION PROFILING THAT CAN MATCH PATIENTS TO THE THERAPIES MOST LIKELY TO WORK. WE AIM FOR KNOWLEDGE AND EXPERTISE THAT WILL ENSURE WOMEN DON’T JUST LIVE LONGER, BUT LIVE BETTER
Botulax for Lasting Youth and Wrinkle-Free Skin
Dr. Moataz Suleiman, Head of Dermatology Department at Cosmesurge Clinics in the UAE
Botulax is considered a therapeutic solution that works by relaxing the muscles responsible for expression lines, restoring the skin's smoothness and youthful appearance. Thanks to its pure and proven-effective formula, it has become a preferred option for those who wish to naturally enhance their appearance. It is also used in various medical treatments, such as for chronic headaches and jawline slimming. It requires no downtime and is easily injected, making it suitable for a modern lifestyle.
In this interview with "Hospitals" magazine, Dr. Moataz Suleiman, a specialist in dermatology, cosmetic, and laser treatments and the Head of the Dermatology Department at Cosmesurge Clinics in the UAE, talks about Botulax and its uses in both cosmetic and therapeutic dermatology.
What is Botulax, and how does it work?
Botulax is a botulinum toxin type A, a purified neurotoxin protein produced by Clostridium botulinum. It works by temporarily blocking the release of acetylcholine at the neuromuscular junction, which reduces muscle contraction. This relaxation of targeted muscles helps smooth dynamic wrinkles caused by repetitive facial movements, giving the skin a more youthful and refreshed appearance.
Is Botulax safe? How does it compare to other botulinum toxin products?
Yes, Botulax is considered safe when administered by trained professionals. It is manufactured under strict purification processes, ensuring high safety and quality standards. Clinical use has demonstrated that Botulax offers reliable efficacy and long-lasting results, with a strong safety profile comparable to that of established botulinum toxin type A products worldwide.
Who is the ideal candidate for Botulax?
The ideal candidate is an individual seeking to reduce expression-related wrinkles such as frown lines, forehead creases, and crow’s feet. Typically, patients range from their late 20s to early 60s. Candidates who prefer naturallooking results, minimal downtime, and a treatment with a predictable duration are wellsuited for Botulax.
In addition to wrinkle relaxation, Botulax (botulinum toxin type A) is also used in therapeutic and aesthetic medicine beyond facial lines. It has applications in conditions like chronic migraine and excessive sweating (hyperhidrosis), and in aesthetics, it can be used for jawline slimming (masseter reduction) and as an adjunct in improving skin quality and acne-prone skin. These broader benefits further highlight its versatility when administered safely by experienced professionals.
Is there any downtime or side effects after treatment?
There is little to no downtime with Botulax. Mild and temporary effects such as redness, swelling, or minor bruising at the injection site may occur, but they usually resolve within 24–48 hours. Most patients can resume their normal daily activities immediately.
BOTULAX IS A BOTULINUM TOXIN TYPE A, A PURIFIED NEUROTOXIN PROTEIN PRODUCED BY CLOSTRIDIUM BOTULINUM. IT WORKS BY TEMPORARILY BLOCKING THE RELEASE OF ACETYLCHOLINE AT THE NEUROMUSCULAR JUNCTION, WHICH REDUCES MUSCLE CONTRACTION.
When will patients see results?
One of the advantages of Botulax is its rapid onset. Noticeable improvements can often be observed within 2–3 days after the treatment. Clinical data indicate that by day 3, a high percentage of patients report visible improvement, making it especially appealing for those seeking quick results.
How long do the results last?
The effects of Botulax generally last about 4 to 5 months, depending on factors such as individual metabolism, muscle activity, lifestyle, and treatment history. Many patients appreciate the consistent duration and fewer touch-ups required.
Can Botulax be combined with other aesthetic treatments?
Yes, Botulax can be safely combined with complementary procedures such as dermal fillers, skin boosters, and energy-based devices like lasers. A personalized treatment plan ensures optimal rejuvenation and naturallooking results.
What should patients avoid before and
after treatment?
Before treatment, patients should avoid alcohol and anti-inflammatory medications to reduce the risk of bruising. After injection, it is recommended to avoid rubbing or massaging the treated area, lying flat for 4–6 hours, and engaging in strenuous exercise the same day. These precautions help ensure proper distribution and effectiveness.
Will Botulax cause a “frozen” look?
When performed by an experienced injector, Botulax provides natural results by softening wrinkles while preserving facial expression. The goal is to enhance, not eliminate, facial movement, so patients look refreshed rather than “frozen.”
What advice would you give to someone hesitant about Botulax?
For those curious but hesitant, I recommend starting with a conservative approach. Working with a qualified medical professional allows for subtle, natural enhancements without dramatic changes. Once patients see the results, they often appreciate how confidence-boosting and discreet the treatment can be.
BOTULAX CAN BE SAFELY COMBINED WITH COMPLEMENTARY PROCEDURES SUCH AS DERMAL FILLERS, SKIN BOOSTERS, AND ENERGY-BASED DEVICES LIKE LASERS. A PERSONALIZED TREATMENT PLAN ENSURES OPTIMAL REJUVENATION AND NATURAL-LOOKING RESULTS.
Clemenceau Medical Center-Beirut: A Model for High-Quality Patient Care
Dr.
Shirin Muhsen,
Vice President of The Quality Department and a Specialist in Breast and Colorectal Tumor Surgery
Clemenceau Medical Center - Beirut has established itself as a leading healthcare institution, with its high-quality care serving as a cornerstone of its reputation. This is primarily a result of its strategic partnerships and unwavering adherence to global healthcare standards. Dr. Shirin Muhsen, Vice President of the Quality Department and a specialist in breast and colorectal tumor surgery at Clemenceau Medical Center, believes that for CMC, international accreditation has become a necessity, not an option, for hospitals in the region, as patients now demand services that meet global benchmarks.
What do you consider to be the most significant impact of international accreditation on a hospital's daily operations and the overall quality of patient care and safety?
International accreditation ensures that hospitals consistently operate under a framework of minimum standards that safeguard patient safety and quality of care. This creates a reliable baseline of practices, systems, and monitoring mechanisms that can be trusted across all departments and services.
Beyond the standards themselves, accreditation fosters a culture of continuous compliance, reflection, and improvement. The discipline of preparing for and maintaining accreditation means that hospitals remain in a constant state of readiness rather than reacting only when inspections occur.
How has Clemenceau Medical Center’s pioneering role as the first hospital in the region to adopt JCI guidelines since its establishment, and to achieve JCI accreditation, along with its affiliation
with Johns Hopkins International, contributed to building a strong patient safety culture?
Since its establishment, Clemenceau Medical Center, Beirut has been the first in the region to adopt JCI guidelines and to achieve JCI accreditation, embedding patient safety as a cornerstone of its mission. This pioneering role laid the groundwork for operational excellence and a continuous drive to enhance patient safety systems.
In addition, CMC’s affiliation with Johns Hopkins International has further strengthened this commitment by providing access to state-
INTERNATIONAL ACCREDITATION ENSURES THAT HOSPITALS CONSISTENTLY OPERATE UNDER A FRAMEWORK OF MINIMUM STANDARDS THAT SAFEGUARD PATIENT SAFETY AND QUALITY OF CARE.
of-the-art guidelines, global best practices, and continuous training opportunities. This affiliation ensures that clinical staff are equipped with the latest knowledge and skills, supporting safe practices across new projects, expansions, and advanced medical procedures. Together, JCI accreditation and the Johns Hopkins affiliation sustain a strong culture where patient safety is deeply embedded in daily practice and consistently maintained over time.
Could you share an example of a specific procedure or action implemented at CMC as a direct result of the JCI accreditation process that has led to improved patient safety outcomes?
One of the direct outcomes of accreditation is the strict alignment with International Patient Safety Goals (IPSGs). For example, CMC enhanced its patient identification process by implementing a dual-identifier system, requiring both patient name and date of birth, to prevent errors in medication administration, diagnostics, and procedures.
While this may seem simple, the effect has been profound in reducing risks of misidentification and enhancing trust between patients and staff. Importantly, improvements like these are not made only in response to an accreditation visit but are maintained continuously as part of CMC’s ongoing monitoring and safety culture.
How does international accreditation influence patient trust in the hospital? Do you notice that patients are becoming more aware of the importance of these accreditations?
Accreditation provides patients with the reassurance that minimum safety and quality standards are in place throughout the facility. While accreditation alone does not guarantee loyalty, patients can clearly see its impact
through the consistency and standardization of their care experience.
Patients today are also more informed and empowered than ever before. With information just a few clicks away, they are aware of their rights, increasingly demand autonomy, and have higher expectations of the institutions caring for them. Accreditation signals transparency and accountability—values that patients now actively seek.
In what ways do international standards foster better collaboration among different medical departments, such as nursing and pharmacy, to ensure patient safety?
International standards provide all disciplines with a shared framework and common safety goals, breaking down silos between departments. Nursing, pharmacy, physicians, and ancillary teams work toward unified objectives, such as medication reconciliation, patient identification or infection control, under the same defined processes.
This creates a culture of joint ownership, where each discipline understands its role in achieving patient safety outcomes. The result is smoother collaboration, fewer communication gaps, and safer care transitions.
In your opinion, has international accreditation become a necessary standard for hospitals in the region?
And if so, why?
Yes, international accreditation has become a necessity rather than an option for hospitals in the region. Healthcare systems are evolving rapidly, and patients now demand services that meet global benchmarks of quality and safety. Accreditation ensures hospitals rise to this expectation. Moreover, it drives institutions to invest in continuous education, patient safety systems, and risk management.
www.cmc.com.lb www.cmc.com.lb www.cmc.com.lb
CMC’S AFFILIATION WITH JOHNS HOPKINS INTERNATIONAL HAS FURTHER STRENGTHENED THIS COMMITMENT BY PROVIDING ACCESS TO STATE-OF-THE-ART GUIDELINES, GLOBAL BEST PRACTICES, AND CONTINUOUS TRAINING OPPORTUNITIES. THIS AFFILIATION ENSURES THAT CLINICAL STAFF ARE EQUIPPED WITH THE LATEST KNOWLEDGE AND SKILLS, SUPPORTING SAFE PRACTICES ACROSS NEW PROJECTS, EXPANSIONS, AND ADVANCED MEDICAL PROCEDURES.
It also enhances recognition among peers, enabling hospitals to collaborate regionally and globally while attracting top talent and building trust with patients.
Based on your experience, what do you see as the next step for Clemenceau Medical Center on its journey toward excellence in patient safety?
CMC has already positioned itself as one of Beirut’s leaders in patient safety and quality of care. The next step is to pursue specialized accreditations across different programs, ensuring that excellence is not only maintained at a general level but also within highly focused areas of practice.
Patients and healthcare partners can expect to see future announcements that reflect this direction. These specialized recognitions will further strengthen CMC’s reputation as a pioneer in adopting international standards
while tailoring them to the unique needs of its patient population.
What message would you convey to other doctors and medical institutions about the importance of adopting international accreditation standards?
I would emphasize that accreditation should not be seen as a checklist exercise to pass an inspection, but rather as a framework that supports safer systems and better patient outcomes. It creates the foundation for reliable care delivery and continuous improvement. For doctors and medical institutions, accreditation also provides a sense of alignment and shared language across teams. It reassures patients, strengthens trust, and elevates the credibility of the institution in the community and among peers. Ultimately, it is an investment not in paperwork, but in people, the patients we serve and the professionals who care for them. www.cmc.com.lb
INTERNATIONAL ACCREDITATION HAS BECOME A NECESSITY RATHER THAN AN OPTION FOR HOSPITALS IN THE REGION. HEALTHCARE SYSTEMS ARE EVOLVING RAPIDLY, AND PATIENTS NOW DEMAND SERVICES THAT MEET GLOBAL BENCHMARKS OF QUALITY AND SAFETY.
Effective Management Strategies for Post-Stroke Hemiplegia
Recovery from the effects of a stroke is a long journey that requires persistence. With the right strategies, however, patients can make significant gains in strength, mobility, and independence at any stage of recovery. Although hemiplegia (paralysis on one side of the body) is one of the most common and challenging outcomes of stroke, substantial recovery is possible through effective management and rehabilitation. This is best achieved through a multidisciplinary plan that integrates personalized physical therapy, specialized interventions such as ConstraintInduced Movement Therapy (CIMT) and Functional Electrical Stimulation (FES), spasticity management, and even mental practice techniques where patients imagine movements to stimulate brain activity. Strong social and emotional support also plays a pivotal role in this recovery journey.
Early Intervention
Immediately after a stroke, the focus is on stabilizing the patient and minimizing further brain damage. This may involve emergency intravenous medications, or in certain cases, endovascular procedures using catheters to deliver drugs directly to the clot or to physically remove it. Managing complications is also critical and may include lowering intracranial pressure, controlling blood pressure, preventing seizures, or managing acute episodes. Surgical intervention may be required in some forms of stroke, such as hemorrhagic stroke caused by aneurysm rupture, to stop bleeding or repair blood vessels.
Beginning rehabilitation as early as possible, ideally within 24 hours, greatly improves outcomes, taking advantage of the brain’s window of neuroplasticity. Early physical, occupational, and speech therapy help maximize functional recovery. Monitoring for muscle tone changes and signs of spasticity (often emerging weeks or months after a stroke) is
also essential, as early stretching and treatment can prevent contractures. A multidisciplinary rehabilitation team provides comprehensive care, combining expertise across specialties to support the patient’s journey toward recovery and independence.
The Multidisciplinary Rehabilitation Team
Physical Therapists (PTs)
Physical therapists focus on restoring and improving gross motor skills such as strength, balance, and mobility. They conduct detailed assessments and design tailored treatment plans, which may include:
• Motor skills training: Exercises to enhance muscle strength and coordination, enabling patients to perform daily activities like walking, standing, and balancing.
• Mobility training: Teaching safe use of assistive devices such as walkers, canes, or wheelchairs to enhance independence.
• Constraint-Induced Movement Therapy (CIMT): Restricting the unaffected limb to encourage use of the weaker limb, retraining the brain and improving function.
• Range-of-Motion therapy: Stretching and mobilization to reduce spasticity and maintain joint flexibility, preventing permanent contractures.
• Gait training: Relearning safe walking patterns, sometimes with robotic assistance to replicate proper movement.
• Functional Electrical Stimulation (FES): Stimulates weak muscles to strengthen and restore control.
• Robotic-assisted rehabilitation: Devices that enable precise, repetitive limb movements to enhance neuromuscular recovery.
• Virtual Reality (VR) therapy: Simulated environments that provide engaging, safe settings for motor training and cognitive stimulation.
BEGINNING REHABILITATION AS EARLY AS POSSIBLE, IDEALLY WITHIN 24 HOURS, GREATLY IMPROVES OUTCOMES, TAKING ADVANTAGE OF THE BRAIN’S WINDOW OF NEUROPLASTICITY. EARLY PHYSICAL, OCCUPATIONAL, AND SPEECH THERAPY HELP MAXIMIZE FUNCTIONAL RECOVERY. MONITORING FOR MUSCLE TONE CHANGES AND SIGNS OF SPASTICITY (OFTEN EMERGING WEEKS OR MONTHS AFTER A STROKE) IS ALSO ESSENTIAL, AS EARLY STRETCHING AND TREATMENT CAN PREVENT CONTRACTURES.
• Balance training: Exercises to strengthen core and leg muscles, improve coordination, and reduce fall risk.
Occupational Therapists (OTs)
Occupational therapists help patients regain independence in daily life and refine fine motor skills. Their interventions include:
• Activities of Daily Living (ADL) retraining: Practicing essential tasks such as dressing, bathing, cooking, and eating.
• Fine motor skill exercises: Targeted activities (e.g., buttoning shirts, stacking blocks, writing) to enhance hand and finger dexterity.
• Adaptive equipment: Training patients in using supportive tools.
• Environmental modifications: Advising on home adaptations, such as installing grab bars in bathrooms or raised toilet seats, to promote independence and safety.
• Cognitive rehabilitation: Addressing challenges in memory, attention, problemsolving, and decision-making that often follow a stroke.
Speech and Language Pathologists (SLPs)
Speech and language pathologists address communication and swallowing difficulties resulting from stroke. Their work includes:
• Assessment and diagnosis: Identifying the type and severity of language or speech impairments, such as receptive aphasia (difficulty understanding language), expressive aphasia (difficulty producing speech), dysarthria (speech muscle weakness), or voice disorders.
• Language and speech therapy: Exercises to improve clarity of speech, comprehension, reading, and writing.
1. Articulation exercises: Strengthening oral muscles for clearer speech.
2. Language drills: Restoring wordfinding, sentence building, and comprehension skills.
3. Augmentative and Alternative Communication (AAC): Teaching use of communication tools as needed.
• Swallowing disorder management (Dysphagia):
1. Safe swallowing assessments.
2. Teaching compensatory strategies, such as postural adjustments during eating or altering food texture (e.g., pureed foods, thickened liquids).
3. Strengthening swallowing muscles with targeted exercises.
• Education and support: Guiding patients and families on managing communication and swallowing issues, reducing frustration, and enhancing quality of life.
Physicians and Rehabilitation Nurses
Specialized physicians and nurses are central members of the rehabilitation team, complementing therapy-based care:
• Neurologists: Diagnose and treat the underlying stroke, identify its cause, and manage acute and long-term complications.
• Physiatrists (rehabilitation medicine specialists): Evaluate functional abilities, coordinate rehabilitation plans, and prescribe therapies or assistive devices.
• Primary care physicians: Provide long-term medical oversight, manage risk factors such as hypertension, diabetes, and high cholesterol, and support lifestyle changes to prevent recurrence.
Rehabilitation nurses help patients integrate newly learned skills into daily routines and ensure continuity of care. Their responsibilities include:
• Reinforcing therapy skills: Supporting practice of walking, dressing, or eating outside of therapy sessions.
• Managing complications: Monitoring bladder and bowel function, providing education on self-care and hygiene, and guiding patients through continence programs.
• Patient and family education: Training caregivers on safe home care practices, recognizing warning signs, and using adaptive equipment.
• Pain and skin management: Controlling discomfort, preventing bedsores, and maintaining skin integrity.
MANAGING
COMPLICATIONS IS ALSO CRITICAL AND MAY INCLUDE LOWERING INTRACRANIAL PRESSURE, CONTROLLING BLOOD PRESSURE, PREVENTING SEIZURES, OR MANAGING ACUTE EPISODES. SURGICAL INTERVENTION MAY BE REQUIRED IN SOME FORMS OF STROKE, SUCH AS HEMORRHAGIC STROKE CAUSED BY ANEURYSM RUPTURE, TO STOP BLEEDING OR REPAIR BLOOD VESSELS.
High Investments and Growing Demand
The Saudi healthcare sector emerges as an international hub for attracting capital
Saudi Arabia’s healthcare sector is flourishing with projects and investment opportunities, ranking sixth globally in this field. The Kingdom aims to increase the private sector’s share in healthcare to 22%, which enhances the appeal for specialized healthcare or pharmaceutical companies to invest. The Ministry of Health’s investment division reported that private healthcare investments in the Kingdom rose by 71% in 2024, supported by foreign inflows. Annual investments are expected to continue rising at a strong pace at least until 2035.
While Saudi Arabia is increasing investments
overall, the focus on healthcare is driving exceptional growth, turning the Kingdom into a magnet for both local and foreign capital across hospital, pharmaceutical, and other health-related projects. According to Investment Minister Khalid Al-Falih, the Saudi healthcare sector now boasts investment opportunities worth over SAR 120 billion. The Global Health Exhibition in Riyadh, held at the end of 2024, saw the launch of nearly SAR 50 billion in new healthcare investments. Al-Falih also highlighted the development of the sector’s digital infrastructure, positioning Saudi Arabia sixth worldwide, in addition to the success of its
THE MINISTRY OF HEALTH’S INVESTMENT DIVISION REPORTED THAT PRIVATE HEALTHCARE INVESTMENTS IN THE KINGDOM ROSE BY 71% IN 2024, SUPPORTED BY FOREIGN INFLOWS.
privatization program, which attracts projects exceeding SAR 120 billion.
He emphasized the Kingdom’s competitive edge as a highly trusted nation for nearly 2 billion Muslims worldwide. Any halal medicine or food produced in Saudi Arabia would thus be highly promising, with wide market appeal. For example, Pakistani investors are seeking licenses and approvals from the Saudi Food and Drug Authority to relocate their industries to the Kingdom for global export.
Saudi Arabia also seeks to finance private healthcare projects and develop hospitals through a dedicated infrastructure fund under the National Development Fund. The significant transformation in healthcare, whether through medical achievements, technological advances, or artificial intelligence, has become a key attraction for global research centers, hospitals, and private investors, promising more investments and further positive health outcomes.
Investment Opportunities Worth SAR 330 Billion
The Kingdom plans to raise healthcare’s contribution to GDP from SAR 199 billion today
to SAR 318 billion by 2030, with the private sector’s share expected at around SAR 145 billion. According to the Ministry of Health, total healthcare investment opportunities in Saudi Arabia reach SAR 330 billion.
The “Invest in Health” conference, part of the 7th Global Health Exhibition (held October 21–23 in Riyadh), showcased numerous opportunities with participation from over 1,000 investors, more than 60 startups, and a wide range of entrepreneurs. The Investor Forum highlighted investment opportunities in healthcare and provided private meeting spaces for investors and companies.
During the event, 138 agreements and MoUs were signed, worth SAR 13.3 billion (USD 4.03 billion). The private healthcare sector is seeing rapid growth through a surge in investment license applications, aligned with Vision 2030 goals to empower the private sector as a key partner in building effective and safe healthcare services. By the close of the Global Health Exhibition, transactions and investments amounted to nearly SAR 50 billion, according to Deputy Minister of Health for Planning and Development, Eng. Abdulaziz Al-Rumaih.
WHILE SAUDI ARABIA IS INCREASING INVESTMENTS
OVERALL, THE FOCUS ON HEALTHCARE IS DRIVING EXCEPTIONAL GROWTH, TURNING THE KINGDOM INTO A MAGNET FOR BOTH LOCAL AND FOREIGN CAPITAL ACROSS HOSPITAL, PHARMACEUTICAL, AND OTHER HEALTHRELATED PROJECTS. ACCORDING TO INVESTMENT
MINISTER KHALID AL-FALIH, THE SAUDI HEALTHCARE SECTOR NOW BOASTS INVESTMENT OPPORTUNITIES WORTH OVER SAR 120 BILLION. THE GLOBAL HEALTH EXHIBITION IN RIYADH, HELD AT THE END OF 2024, SAW THE LAUNCH OF NEARLY SAR 50 BILLION IN NEW HEALTHCARE INVESTMENTS.
SAR 72 Billion by 2030
Saudi Arabia ranks first regionally in healthcare spending, witnessing major growth in foreign cash inflows into the sector. In recent years, these investments grew at an average annual rate of 11%. The Kingdom aims to increase private sector participation in healthcare to 22%, boosting opportunities for healthcare companies. These investments extend beyond healthcare delivery, reaching all areas of the sector. In pharmaceuticals, the Kingdom targets nearly SAR 72 billion in investments by 2030. Saudi pharmaceutical manufacturing enjoys global credibility, demand, and international recognition, attracting multinational companies to open factories or invest heavily in existing local firms. Investment agreements cover major areas such as artificial intelligence, pharmaceuticals, and medical devices, alongside new opportunities in modern healthcare models to match global advancements. Reports highlight at least four growth drivers for Saudi private healthcare: demographic
expansion among citizens and expatriates, National Transformation Program goals, low hospital penetration rates, and insurance sector developments. This is reinforced by major healthcare IPOs on the Saudi stock market, including Dr. Sulaiman Al-Habib Medical Group’s 2020 listing, and Faqih Healthcare Group’s June 2024 IPO, the largest of that year at SAR 2.9 billion (USD 764 million). Gulf subsidiary of Aster DM Healthcare is also considering a USD 250 million acquisition to boost its presence in Saudi Arabia. These trends, which continued rising into 2025, align with a decade-long pipeline of healthcare investment projects that signal an unprecedented sectoral boom, possibly the largest in the region. Observers expect Saudi healthcare to maintain strong performance, with profit growth between 12–14% in Q2 and Q3 2025, potentially rising to 14–16% by Q4 2025 and Q2 2026. Key drivers include Vision 2030 healthcare initiatives, expansion of facilities and medical tourism, and rapid adoption of digital health technologies.
IN PHARMACEUTICALS, THE KINGDOM TARGETS NEARLY SAR 72 BILLION IN INVESTMENTS BY 2030. SAUDI PHARMACEUTICAL MANUFACTURING ENJOYS GLOBAL CREDIBILITY, DEMAND, AND INTERNATIONAL RECOGNITION, ATTRACTING MULTINATIONAL COMPANIES TO OPEN FACTORIES OR INVEST HEAVILY IN EXISTING LOCAL FIRMS.
ACIBADEM HEALTHCARE GROUP... Two Babies with Liver
Failure from Georgia and Libya Treated in Türkiye
Two babies, a two-year-old from Libya and a four-month-old from Georgia, underwent successful liver transplants performed by Turkish doctors at Acıbadem in Türkiye.
Liver transplantation, which involves removing a portion of a healthy person’s liver and transplanting it into a patient to save their life, sounds like a miracle. Yet, for experienced transplant surgeons, it is part of their daily routine. Performing transplants on two babies from different parts of the world within just a few days was a remarkable achievement even for Prof. Murat Kılıç, Assoc. Prof. Cahit Yılmaz, and the entire team. They have performed more than two thousand liver transplants to date, including many pediatric cases, making them a very experienced team in this field.
Two Different Journeys from Despair to Hope
Two babies sharing the same fate, one from Libya and the other from Georgia, traveled with their families to Türkiye for life-saving liver transplant surgeries. Both families made the long journey in search of a cure for their children who were suffering from liver failure. Led by Prof. Murat Kılıç, the team performed a liver transplant for Hatan, a 2-year-old girl from Libya, using liver tissue donated by her father, and for Saba, a 4-month-old boy from Georgia, using liver tissue donated by his mother. As the families rejoiced at their babies beginning a second chance at life, Prof. Kılıç shared that both children were in good health and would soon be discharged.
TWO BABIES SHARING THE SAME FATE, ONE FROM LIBYA AND THE OTHER FROM GEORGIA, TRAVELED WITH THEIR FAMILIES TO TÜRKIYE FOR LIFE-SAVING LIVER TRANSPLANT SURGERIES. BOTH FAMILIES MADE THE LONG JOURNEY IN SEARCH OF A CURE FOR THEIR CHILDREN WHO WERE SUFFERING FROM LIVER FAILURE.
Hatan’s Story
Hatan was diagnosed with biliary atresia, a serious congenital condition in which the liver’s bile ducts are missing, when she was just three weeks old. Her father took her from Libya to Egypt for surgery, where she underwent the Kasai procedure. This procedure involves removing the blocked bile ducts and gallbladder and replacing them with a segment of the child’s own small intestine. However, it was not a permanent solution, and Hatan eventually needed a liver transplant to regain her health. Her father volunteered to be her donor.
With the support of the Libyan Ministry of Health, Hatan and her father traveled to Acıbadem in İzmir, Türkiye. After completing the necessary tests, baby Hatan underwent surgery. A portion of her father’s liver was successfully transplanted into Hatan. Before the transplant, she was in serious condition and unable to walk. After the surgery, she recovered quickly and even began walking again.
Prof. Sema Aydoğdu, a specialist in pediatric gastroenterology, explained that the absence of bile ducts is the most common reason for liver transplants in children. Before the transplant, Hatan was in the final stages of liver failure. Her abdomen was severely swollen due to malnutrition and fluid accumulation, which also caused her organs to enlarge. All signs of liver insufficiency were present, but she was brought to the hospital at exactly the right time for a transplant. Now, following the surgery, her liver functions have returned to normal, and the team plans to discharge her within a few days.
Hatan’s father, said: "We went through very difficult times. Watching my daughter’s health deteriorate was devastating and broke my heart. We came to Türkiye and to Acıbadem for
WITH THE SUPPORT OF THE LIBYAN MINISTRY OF HEALTH, HATAN AND HER FATHER TRAVELED TO ACIBADEM IN İZMIR, TÜRKIYE. AFTER COMPLETING THE NECESSARY TESTS, BABY HATAN UNDERWENT SURGERY. A PORTION OF HER FATHER’S LIVER WAS SUCCESSFULLY TRANSPLANTED INTO HATAN. BEFORE THE TRANSPLANT, SHE WAS IN SERIOUS CONDITION AND UNABLE TO WALK. AFTER THE SURGERY, SHE RECOVERED QUICKLY AND EVEN BEGAN WALKING AGAIN.
the liver transplant. Now my daughter is well, and we are very happy. I would like to thank the Libyan government, doctors, Acıbadem, and the Turkish government for giving her this chance."
Saba’s Story
Saba was diagnosed with liver cirrhosis when he was just two months old. The only treatment option was liver transplantation, and it had to be done urgently. His family began searching for a way to give their little son a new lease on life.
His mother recalled those days: "Symptoms began just 10 days after he was born. Since
there was no procedure available in our country, his condition worsened day by day, and we decided to come to Türkiye as a family."
The family contacted Acıbadem and traveled to Türkiye for treatment. Both parents were prepared to be donors for their baby, but the father was not a suitable match. The mother became the donor.
Acıbadem surgeons successfully performed the operation, removing a portion of the mother’s liver and transplanting it into baby Saba, giving him the chance to live a healthy life. In a way, the mother gave life to her son for the second time.
ACIBADEM SURGEONS SUCCESSFULLY PERFORMED THE OPERATION, REMOVING A PORTION OF THE MOTHER’S LIVER AND TRANSPLANTING IT INTO BABY SABA, GIVING HIM THE CHANCE TO LIVE A HEALTHY LIFE.
Prof. Murat Kılıç described Saba’s condition: "His situation was an emergency. The liver’s clotting function had stopped working. Without an urgent transplant, he could have died. If we had not been able to perform the transplant within a week, we would have lost him. We urgently performed a transplant from the mother. The baby was four months old and weighed six kilograms, but the operation went well. We have considerable experience in pediatric liver transplantation. Baby Saba’s liver functions have returned to normal. It has been one week since the
transplant, and he will be discharged in a few days."
Saba’s mother said that her son’s condition improved after the operation and that they are very happy. She added that they hope he continues to get better every day and expressed their deep gratitude to all the doctors and the entire team at Acıbadem.
THE BABY WAS FOUR MONTHS OLD AND WEIGHED SIX KILOGRAMS, BUT THE OPERATION WENT WELL.
Acıbadem Healthcare Group is one of the leading destinations for liver transplantation in Türkiye. Many patients from around the world choose Acıbadem for their treatment thanks to its extensive experience, high success rates, and patientcentered care. To date, Acıbadem has successfully performed more than 5,000 liver transplants, including pediatric cases, complex surgeries, and combined kidney-liver transplants. These procedures are carried out at three dedicated liver transplant centers located in İstanbul, İzmir, and Bursa. If you’d like to learn more, visit acibademinternational.com and share your condition with us through the contact form. Our expert team will contact you within a few hours.
Breaking the Stone: Understanding & Preventing Kidney Stones
Dr. Elfadil El Malik, Consultant Urologist at Al-Ahli Hospital/Qatar
In a region known for its soaring temperatures and long summers, kidney stones are not just a medical concern, they're a public health issue. At Al-Ahli Hospital, Consultant Urologist Dr. Elfadil El Malik has treated hundreds of patients suffering from the excruciating pain of kidney stones. His message is clear and timely: kidney stones are preventable, treatable, and should never be ignored. In this exclusive feature, Dr. El Malik explains what causes kidney
KIDNEY STONES ARE HARD, CRYSTALLINE DEPOSITS THAT FORM INSIDE THE KIDNEYS WHEN MINERALS & SALTS IN THE URINE BECOME CONCENTRATED.
stones, who is at risk, how they can be treated, and, most importantly, how they can be avoided.
A Silent Stone, A Loud Pain
Kidney stones are hard, crystalline deposits that form inside the kidneys when minerals and salts in the urine become concentrated. The most common types are made of calcium oxalate, uric acid, or struvite. “Many people don’t realize they have kidney stones until they experience severe
pain,” says Dr. El Malik. “It can begin suddenly, often starting in the back or side, and radiate to the lower abdomen or groin. It’s a pain patients never forget.”
Other symptoms may include:
• Nausea and vomiting
• Blood in the urine
• Frequent or painful urination
• Fever or chills (if infection is present)
Why Are Kidney Stones So Common in the Gulf?
Dr. El Malik explains that environmental, dietary, and lifestyle factors contribute to the high incidence of kidney stones in Qatar and other Gulf countries.
“The hot climate leads to chronic dehydration, which means the urine becomes more concentrated. That alone increases the risk of stone formation.”
Additional risk factors include:
• High consumption of salt, red meat, and sugary drinks
• Low fluid intake
• Genetics and family history
• Sedentary lifestyle
• Medical conditions like obesity, diabetes, and inflammatory bowel disease Diagnosis: Imaging the Enemy
Most kidney stones can be diagnosed through:
• Ultrasound: A non-invasive first-line imaging tool
• CT Scan: The gold standard for diagnosing stone size, location, and number
• Urine and Blood Tests: To detect infections, pH levels, and metabolic imbalances
“Once we understand the size and position of the stone, we can customize the treatment approach,” says Dr. El Malik.
Treatment: From Medication to Minimally Invasive Surgery
The treatment for kidney stones depends on their size, location, and whether they are causing obstruction or infection.
For small stones:
• Increased fluid intake
• Pain relievers
• Medications to relax the ureters and help pass the stone naturally
For larger or stubborn stones:
• Extracorporeal Shock Wave Lithotripsy (ESWL): Sound waves break the stone into smaller fragments
• Ureteroscopy (URS): A thin scope is passed into the ureter to extract or laser-fragment the stone
• Percutaneous Nephrolithotomy (PCNL): A keyhole procedure used for large or complex stones
“At Al-Ahli Hospital, we’re equipped with advanced technologies for minimally invasive stone removal,” Dr. El Malik explains. “This allows for faster recovery, less pain, and better outcomes.”
Prevention: Hydration is Key, but Not the Only One
While treatment has advanced dramatically, Dr. El Malik emphasizes that prevention remains the most powerful tool.
His top prevention tips include:
• Drink at least 2.5 to 3 liters of water daily, especially in hot climates
• Limit sodium, animal proteins, and processed foods
• Reduce intake of oxalate-rich foods like spinach, beets, and nuts (especially for those with a history of calcium oxalate stones)
• Maintain a healthy weight
• Stay physically active
• Follow up with a specialist if you've had kidney stones before
“Once you’ve had a kidney stone, you have a 50% chance of developing another within five years if no lifestyle changes are made,” he warns.
THE MOST COMMON TYPES ARE MADE OF CALCIUM OXALATE, URIC ACID, OR STRUVITE. “MANY PEOPLE DON’T REALIZE THEY HAVE KIDNEY STONES UNTIL THEY EXPERIENCE SEVERE PAIN,” SAYS DR. EL MALIK. “IT CAN BEGIN SUDDENLY, OFTEN STARTING IN THE BACK OR SIDE, AND RADIATE TO THE LOWER ABDOMEN OR GROIN. IT’S A PAIN PATIENTS NEVER FORGET.”
Tailored Care at Al-Ahli Hospital
One of the key advantages at Al-Ahli Hospital is the personalized care pathway offered to each patient. Dr. El Malik and his team not only treat the stone but also investigate the root cause.
“We don’t just remove the stone and send the patient home,” he says. “We perform a full metabolic workup, review dietary habits, and work closely with dietitians and primary care doctors to ensure recurrence is minimized.”
Moreover, the hospital offers kidney stone screening packages and comprehensive urology services that are both patient-centered and time-efficient.
Raising Awareness: A Community Responsibility
Beyond the clinic, Dr. El Malik is a strong advocate for public education on kidney health. He supports awareness campaigns and corporate wellness talks that help people recognize early symptoms and adopt kidneyfriendly habits.
“Many patients come to us in pain, confused, or scared. But with the right information and support, they leave empowered.” He also encourages routine checkups, especially for individuals with a family history or other risk factors.
Final Word: Don’t Wait for the Pain
Dr. Elfadil El Malik leaves us with this clear message: “Kidney stones are a warning sign. Your body is telling you something is off. Don’t ignore the symptoms, and don’t wait for the pain to strike. Prevention is simpler than you think, and treatment is more effective the earlier we act.” At Al-Ahli Hospital, the commitment to urological health goes beyond diagnosis and surgery. It’s about creating a system of care that empowers patients to make informed choices, before stones form, not just after.
BEYOND THE CLINIC, DR. EL MALIK IS A STRONG ADVOCATE FOR PUBLIC EDUCATION ON KIDNEY HEALTH. HE SUPPORTS AWARENESS CAMPAIGNS AND CORPORATE WELLNESS TALKS THAT HELP PEOPLE RECOGNIZE EARLY SYMPTOMS AND ADOPT KIDNEYFRIENDLY HABITS.
Non-Transfusion-Dependent Thalassemia
Professor Ali Taher, Lebanese Professor Leads Breakthrough in Thalassemia Treatment
In a major achievement for Lebanese medicine, Professor Ali Taher, a leading expert in hematology and oncology, has published the results of a groundbreaking clinical trial in the prestigious medical journal
The Lancet. Dr. Taher, who holds multiple key positions at the American University of Beirut (AUB) and the Chronic Care Center, was the lead researcher on a clinical trial for a new thalassemia treatment. The successful outcome of this study is a testament to Lebanon’s medical and scientific excellence.
This achievement represents the world’s first proof of the efficacy of an oral, diseasemodifying therapy for patients with alpha- and beta-thalassemia who are not dependent on regular blood transfusions, offering new hope to patients in Lebanon, the region, and worldwide. It also affirms Lebanon’s ability, despite all challenges, to lead medical research that impacts global healthcare.
What was your role in creating and leading this global study? What were the biggest challenges you faced in making it happen?
I had the honor of leading this multinational study, which represents the first strong scientific evidence for the efficacy of an oral, disease-modifying therapy in non-transfusiondependent thalassemia (NTDT). In addition to scientific oversight, my role included designing the study protocol in collaboration with an international team of experts and ensuring adherence to the highest standards of clinical research. One of the main challenges we faced was recruiting a sufficient number of patients from various countries, while ensuring that all research teams adhered to strict procedures despite differences in healthcare systems and logistical environments. Moreover, the global COVID-19 pandemic posed unprecedented obstacles to our workflow.
In your opinion, how does the success of this study reflect the scientific stature of Lebanese physicians and their contributions to advancing treatment and medical research globally, despite
Lebanon’s difficult circumstances?
This achievement clearly demonstrates that medical and scientific innovation know no boundaries. Lebanese physicians, particularly those at the American University of Beirut, have repeatedly proven their ability to lead in clinical research and to actively contribute to the development of modern therapies.
Despite severe economic and living crises, we have maintained our position as key contributors to scientific research and proven that Lebanon can continue advancing medicine worldwide. I would also note my participation in two major studies on thalassemia: one on non-transfusion-dependent thalassemia, where I served as principal investigator, and another on transfusion-dependent thalassemia, where I was a co-investigator. In both, I was involved in protocol development and oversight. The main difference between them lies in the therapeutic goal: in NTDT, we aim to raise hemoglobin levels; in transfusion-dependent thalassemia, the goal is to reduce the frequency of transfusions or extend the interval between them.
How does this achievement enhance the position of the American University of Beirut and the Chronic Care Center in Lebanon as a regional hub for research and clinical excellence?
This study once again confirms that AUB is a true scientific beacon in the region, capable through its physicians of leading research published in The Lancet, one of the world’s most prestigious journals. It reflects our commitment to evidence-based research and to serving patients both locally and globally.
The strength of this study lies in multiple dimensions. It is not merely an academic publication from AUB and the Chronic Care Center, which already lends it credibility. More importantly, its results will directly contribute to the U.S. Food and Drug Administration (FDA) approval process for the drug. This means that Lebanese research efforts will help secure global approval of a therapy, demonstrating Lebanon’s role in medical innovation and paving the way for making this treatment available worldwide, including in Lebanon.
DESPITE SEVERE ECONOMIC AND LIVING CRISES, WE HAVE MAINTAINED OUR POSITION AS KEY CONTRIBUTORS TO SCIENTIFIC RESEARCH AND PROVEN THAT LEBANON CAN CONTINUE ADVANCING MEDICINE WORLDWIDE. I WOULD ALSO NOTE MY PARTICIPATION IN TWO MAJOR STUDIES ON THALASSEMIA: ONE ON NONTRANSFUSIONDEPENDENT THALASSEMIA, WHERE I SERVED AS PRINCIPAL INVESTIGATOR, AND ANOTHER ON TRANSFUSIONDEPENDENT THALASSEMIA, WHERE I WAS A COINVESTIGATOR.
What motivated you to lead this global clinical trial? What objectives did you set when designing it?
My driving motivation was a deep commitment to improving the quality of life for patients with thalassemia, particularly those who do not receive regular blood transfusions and whose treatment needs remain unmet. The primary objective was to evaluate the efficacy and safety of “Mitapivat” as an oral therapy that can sustainably raise hemoglobin levels, reduce disease burden, and transform clinical care for these patients.
Speaking of this patient group, could you explain what non-transfusion-dependent thalassemia (NTDT) is and what complications it involves?
NTDT includes conditions such as thalassemia intermedia and hemoglobin H disease, where patients have chronic anemia but do not require regular transfusions to survive. They may occasionally need transfusions during critical periods such as pregnancy, severe infection, or after an emergency splenectomy.
NTDT can still cause serious complications. Patients suffer from chronic anemia, leading to persistent fatigue and weakness. Ineffective red blood cell production disrupts iron metabolism, resulting in iron overload due to increased absorption. Other common complications include thrombosis, pulmonary hypertension, splenomegaly, osteoporosis, and leg ulcers.
How does NTDT differ from transfusiondependent thalassemia in terms of treatment needs and patient challenges?
When discussing thalassemia, we distinguish between three categories:
• Thalassemia trait carriers: These individuals show no symptoms but carry the genetic mutation. They need to be aware of the risk of having children with thalassemia major if they marry another carrier.
• Thalassemia intermedia (NTDT): This is the group targeted by our study. Unlike thalassemia major, these patients do not need lifelong transfusions to survive. However, their hemoglobin levels remain
chronically low, leading to fatigue and complications. They may still require transfusions in certain situations such as pregnancy, before surgery, or after trauma.
• Thalassemia major (transfusiondependent): These patients require regular transfusions every 2–3 weeks for survival.
Our current study aims to provide an oral therapy for NTDT patients to raise hemoglobin levels and improve daily living, which is always the ultimate goal of research.
Why have treatment options for these patients been lacking until now?
Most previous research focused on transfusiondependent patients, as their needs were considered more urgent. NTDT patients were often mistakenly thought to be at lower risk, and their complex needs were not adequately addressed. These delayed studies aimed at modifying their disease course.
How does “Mitapivat” work as an oral, disease-modifying therapy in thalassemia?
Mitapivat is an activator of the pyruvate kinase enzyme in red blood cells. It improves energy production within the cell, reduces cell breakdown, and consequently raises hemoglobin levels. This cellular adjustment allows the drug to alter the natural course of the disease and relieve chronic anemia symptoms.
What was the safety and tolerability profile of the drug during the trial? Were there any unexpected findings that could influence future research directions?
The drug demonstrated a very favorable safety profile, with most side effects being mild to moderate and manageable. No serious unexpected adverse events occurred, reinforcing our confidence in its broader potential use. However, long-term monitoring and additional studies will be needed to confirm its safety over time.
How could “Mitapivat” change the global treatment landscape for NTDT patients?
THE THALASSA AND BEYOND TRIALS PAVED THE WAY FOR A DEEPER UNDERSTANDING OF NTDT PATIENTS’ NEEDS AND HIGHLIGHTED THE EFFICACY OF TREATMENTS THAT ADJUST IRON BALANCE OR STIMULATE HEMOGLOBIN PRODUCTION. THE MITAPIVAT STUDY BUILDS ON THIS FOUNDATION BUT TAKES A FURTHER STEP BY DIRECTLY MODIFYING THE DISEASE PROCESS AT THE CELLULAR LEVEL, MAKING IT A NATURAL CONTINUATION OF THIS RESEARCH PATH.
Mitapivat represents a paradigm shift because, for the first time, it offers an effective, sustainable oral option for these patients. Instead of relying on intermittent transfusions or non-targeted therapies, they can now receive a treatment that modifies the disease itself, potentially transforming care strategies worldwide.
How does this study build upon previous efforts at AUB and the Chronic Care Center, such as the THALASSA and BEYOND trials?
The THALASSA and BEYOND trials paved the way for a deeper understanding of NTDT patients’ needs and highlighted the efficacy of treatments that adjust iron balance or stimulate hemoglobin production. The Mitapivat study builds on this foundation but takes a further step by directly modifying the disease process at the cellular level, making it a natural continuation of this research path.
What impact could these results have on patients’ quality of life and long-term health?
Sustainably raising hemoglobin levels directly
improves energy, concentration, and reduces complications of chronic anemia, such as splenomegaly or osteoporosis. Over time, it can decrease the need for medical interventions and lessen the psychological and social burden on patients and their families.
What are the next steps after publishing these results in The Lancet?
The next step is to work with regulatory authorities worldwide to secure clinical approval of the drug. We also plan to conduct additional studies in different age groups, including children, and to assess its role in integrated treatment strategies. In parallel, we are raising awareness among physicians and medical centers to incorporate this breakthrough into clinical practice.
Further publications on transfusiondependent thalassemia are also in the pipeline. It is important to remember that the ultimate mission of medicine is not only to prevent disease but also to promote health and wellbeing. This principle has always guided my work, and I believe the results of this study represent a meaningful step toward fulfilling that mission for thalassemia patients worldwide.
NTDT INCLUDES CONDITIONS SUCH AS THALASSEMIA INTERMEDIA AND HEMOGLOBIN H DISEASE, WHERE PATIENTS HAVE CHRONIC ANEMIA BUT DO NOT REQUIRE REGULAR TRANSFUSIONS TO SURVIVE. THEY MAY OCCASIONALLY NEED TRANSFUSIONS DURING CRITICAL PERIODS SUCH AS PREGNANCY, SEVERE INFECTION, OR AFTER AN EMERGENCY SPLENECTOMY.
From Good to Exceptional: The Practices and Metrics that Drive Medical Travel Success
Renée-Marie Stephano, CEO, Global Healthcare Accreditation
The Middle East continues to position itself as a global hub for advanced healthcare services, attracting patients from across the GCC, Africa, and Asia. Governments and private health systems have invested heavily in world-class hospitals, state-of-the-art facilities, and internationally trained staff. Yet, while infrastructure is essential, what truly differentiates one hospital from another in the eyes of international or traveling patients is not simply what is built, but how the entire patient journey is delivered, measured, and continuously improved. Today, senior hospital executives face a critical question: Will your hospital remain just another option in a crowded field, or will you invest in a sustainable medical travel strategy that secures long-term resilience and trusted patient loyalty. Global Healthcare Accreditation (GHA) works with leading hospitals and clinics worldwide to transform programs from good to exceptional, ensuring measurable outcomes, enhanced reputation, and long-term sustainability.
The Opportunity – and the Risk
The global medical travel market is growing rapidly, with projections reaching hundreds of billions of dollars annually. For GCC countries, medical travel offers a dual opportunity:
retaining outbound patients who currently seek care elsewhere and attracting inbound patients from neighboring regions. Countries like Saudi Arabia and the UAE are already embedding medical tourism into their national strategies as part of broader visions for economic diversification. However, this opportunity comes with risk. International patients today are well informed and demand not just clinical excellence, but seamless, safe, and trustworthy experiences. A program that is not fully prepared, or inconsistent in service delivery, risks damaging both reputation and return on investment. In today’s competitive market, a single negative patient experience can reverberate quickly through social media, embassies, and referring physicians.
Readiness – Building the Foundation for Success
Success in medical travel requires more than marketing campaigns and international patient departments. It requires a readiness strategy that ensures all elements of the patient journey - from initial inquiry to posttreatment follow-up - are aligned with global best practices. Before pursuing aggressive marketing, hospitals and clinics must ensure internal and external readiness.
COUNTRIES LIKE SAUDI ARABIA AND THE UAE ARE ALREADY EMBEDDING MEDICAL TOURISM INTO THEIR NATIONAL STRATEGIES AS PART OF BROADER VISIONS FOR ECONOMIC DIVERSIFICATION. HOWEVER, THIS OPPORTUNITY COMES WITH RISK. INTERNATIONAL PATIENTS TODAY ARE WELL-INFORMED AND DEMAND NOT JUST CLINICAL EXCELLENCE, BUT SEAMLESS, SAFE, AND TRUSTWORTHY EXPERIENCES.
INTERVIEWS
Internal readiness means having:
• Adequate and clearly defined staffing for international patient care.
• Multilingual, culturally trained teams for patient and family engagement.
• Streamlined workflows for scheduling, admissions, and discharges.
• Established clinical pathways for highdemand specialties.
External readiness includes:
• A clear, consistent brand identity in target markets.
• Strategic relationships with facilitators, insurers, and referring providers.
• Flexible service offerings tailored to market-specific needs.
Healthcare organizations must evaluate their readiness across multiple dimensions: governance, operations, staff training, cultural competency, patient communication, and coordination with external partners such as hotels and transportation providers. GHA’s experience demonstrates that organizations who invest in readiness achieve faster patient conversion, improved satisfaction, and greater trust among payers and governments. Across the region, GHA-accredited and certified organizations like King Faisal Specialist Hospital & Research Center (KFSH&RC), Dallah Hospital Al Nakheel, Dr. Sulaiman Al Habib Al Khobar hospital, and M42 have embraced this readiness model, training staff to international standards, creating digital entry points for global patients, and embedding cultural sensitivity into service delivery.
Metrics That Matter – Going Beyond the Usual
For senior leaders, metrics are essential. They not only demonstrate return on investment but also serve as the foundation for continuous improvement. Most healthcare organizations already measure the right things at a high level—business performance and clinical quality KPIs that are fundamental to any health system. However, when it comes to medical travel, world-class programs go further. They segregate data specific to international patients and
monitor outcomes across three pillars: clinical quality, business performance, and patient experience. This distinction is vital. Research consistently shows that excellent patient experience has a direct, positive influence on both clinical outcomes and business performance. For example, medical travelers who feel supported across the entire journey are more likely to adhere to treatment plans, report fewer complications, and recommend the provider to others.
By isolating medical travel–specific data, hospitals can uncover unique trends, address gaps, and demonstrate accountability to international payers and ministries of health.
Hospitals and clinics that excel in medical travel track a comprehensive set of metrics, such as:
• Business KPIs: Patient inquiries, referral sources, conversion rates, average revenue per international patient, true cost-ofservice figures, pricing differentials, and payer mix.
• Clinical Outcomes (segmented for traveling patients): Complication rates, infection control data, readmission rates, and outcomes by country of origin—critical for demonstrating safety and reliability to global stakeholders.
• Patient Experience Across the Journey: Going beyond standard satisfaction surveys to measure the full continuum of care for medical travelers, from pre-arrival communication to posttreatment follow-up.
• Hospitality & Support Services: Quality of accommodation, airport transfers, concierge services, and the experiences of accompanying family members—all of which are central to the patient journey.
By capturing and analyzing data that reflects not just the hospital stay but the entire medical travel journey, executives gain the insights needed to strengthen differentiation, close service gaps, and demonstrate
ACROSS THE REGION, GHA-ACCREDITED AND CERTIFIED ORGANIZATIONS LIKE KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTER (KFSH&RC), DALLAH HOSPITAL AL NAKHEEL, DR. SULAIMAN AL HABIB AL KHOBAR HOSPITAL, AND M42 HAVE EMBRACED THIS READINESS MODEL, TRAINING STAFF TO INTERNATIONAL STANDARDS, CREATING DIGITAL ENTRY POINTS FOR GLOBAL PATIENTS, AND EMBEDDING CULTURAL SENSITIVITY INTO SERVICE DELIVERY.
accountability across clinical, business, and experiential outcomes.
At Global Healthcare Accreditation (GHA), we help organizations identify, refine, and implement the KPIs that matter most; ensuring your medical travel program achieves measurable impact, sustainable growth, and stronger global positioning.
Differentiation – Standing Out in a Competitive Market
In an environment where many hospitals promote “international quality,” differentiation is key. Accreditation and certification programs focused specifically on medical travel provide a credible, external validation that builds confidence among patients, payers, and government stakeholders. Differentiation also means delivering experiences that go beyond the clinical encounter: culturally sensitive communication, streamlined visa and travel processes, personalized care coordination, and seamless integration of medical and hospitality services. The institutions that succeed in this area create not only satisfied patients but passionate advocates who generate referrals and repeat visits.
Notably, GHA-accredited organizations in the region are demonstrating this:
• KFSH&RC leverages user-friendly avenues for prospective patients to initiate contact, including international phone lines, multilingual online platforms, and regionally tailored outreach channels
• Dallah Hospital Al Nakheel has pioneered a “Digital Front Door” for international patients.
• Dr. Sulaiman Al Habib Al Khobar hospital enhances cultural comfort with entertainment and advanced telemedicine.
• M42 in the UAE assigns Ambassadors to every international patient, ensuring personalized guidance from arrival to departure.
These institutions showcase how differentiation is not abstract—it’s practical, visible, and impactful.
Patient Experience – The Ultimate Differentiator
At the heart of medical travel is trust. Research conducted by GHA shows that 90% of patients consider accreditation an important factor in choosing a provider abroad, and 80% say it increases their trust in care quality.
This is especially relevant in the GCC, where patients and families weigh multiple options for specialized or elective procedures.
Exceptional patient experience is not just about amenities; it is about consistency, transparency, and empathy at every step of the journey.
From timely communication before travel to coordinated discharge and aftercare, each interaction is a building block of trust. Hospitals that prioritize and measure patient experience consistently outperform competitors in both satisfaction and business results.
From Good to Exceptional: The Path Forward
The Middle East stands at a pivotal moment. Investment has created a strong foundation, but sustainable success in medical travel requires a shift from infrastructure to outcomes, from facilities to patient journeys. However, the transformation from good to exceptional in medical travel doesn’t happen by accident. It requires aligning strategy, readiness, and patient experience with market realities - and then executing consistently. Hospitals that focus on readiness, comprehensive metrics, differentiation, and exceptional patient experience will not only capture market share but also position themselves as trusted global leaders. Global Healthcare Accreditation supports healthcare organizations worldwide in making this transformation. Through readiness assessments, certification, and accreditation, GHA helps hospitals move from good to exceptional—delivering measurable business results while ensuring patients receive the safe, trusted, and exceptional care they deserve.
IN AN ENVIRONMENT WHERE MANY HOSPITALS PROMOTE “INTERNATIONAL QUALITY,” DIFFERENTIATION IS KEY. ACCREDITATION AND CERTIFICATION PROGRAMS FOCUSED SPECIFICALLY ON MEDICAL TRAVEL PROVIDE A CREDIBLE, EXTERNAL VALIDATION THAT BUILDS CONFIDENCE AMONG PATIENTS, PAYERS, AND GOVERNMENT STAKEHOLDERS. DIFFERENTIATION ALSO MEANS DELIVERING EXPERIENCES THAT GO BEYOND THE CLINICAL ENCOUNTER: CULTURALLY SENSITIVE COMMUNICATION, STREAMLINED VISA AND TRAVEL PROCESSES, PERSONALIZED CARE COORDINATION, AND SEAMLESS INTEGRATION OF MEDICAL AND HOSPITALITY SERVICES.
1. GHA Patient Impact Survey, August 2025
Protecting Women’s Health: The Critical Role of HPV Vaccination
Dr. Ahmad Khalafallah,
Obstetrician and Gynecologist at Al-Ahli Hospital/Qatar
In the global effort to reduce preventable diseases among women, few medical breakthroughs have been as impactful and as underutilized as the Human Papillomavirus (HPV) vaccine. At the forefront of raising awareness in Qatar is Dr. Ahmad Khalafallah, a respected figure in women’s health and gynecological care. His message is urgent yet hopeful: HPV vaccination can prevent the vast majority of cervical cancer cases, and every woman deserves to be informed and protected.
IT’S NOT JUST ABOUT PROTECTING AGAINST A VIRUS, IT’S ABOUT PROTECTING A WOMAN’S FUTURE, HER FERTILITY, AND HER PEACE OF MIND.
Understanding HPV and Its Risks
HPV is the most common sexually transmitted infection worldwide. In fact, most sexually active individuals will contract it at some point in their lives. While many strains of HPV clear on their own, certain high-risk types are directly linked to cervical cancer, as well as other genital and oropharyngeal cancers.
“HPV is silent,” Dr. Khalafallah explains. “It often shows no symptoms until it has already progressed. That’s why prevention through vaccination is so important.”
According to the World Health Organization, over 95% of cervical cancer cases are caused by HPV, and cervical cancer remains one of the leading causes of cancer-related death in women globally. But this is where vaccination changes the story.
A Powerful Prevention Tool
Dr. Khalafallah emphasizes that the HPV vaccine is safe, effective, and lifesaving. “It’s not just about protecting against a virus, it’s about protecting a woman’s future, her fertility, and her peace of mind.” The vaccine is most effective when administered before exposure to the virus, ideally between the ages of 9 and 14. However, catch-up vaccinations are also recommended for older age groups, including women up to the age of 26, and in some cases, even beyond, depending on risk factors and medical advice.
Breaking the Stigma and Myths
Despite its proven efficacy, the HPV vaccine still faces resistance in some regions due to misinformation, cultural taboos, and the mistaken belief that it encourages risky behavior.
“This is not a vaccine about lifestyle,” Dr. Khalafallah states firmly. “It is a cancer prevention vaccine. It’s no different from giving a child a polio or hepatitis vaccine. The focus should always be on health, not judgment.”
He also addresses the misconception that HPV only affects women. Men can carry and transmit the virus, and in some cases, develop HPV-related cancers themselves. “Widespread vaccination, including for boys, helps stop the virus at a community level,” he adds.
A Regional Call to Action
In Qatar and across the region, public health authorities have taken steps to introduce HPV vaccination into preventive care programs.
Dr. Khalafallah sees this as a critical step, but emphasizes that greater public education, physician advocacy, and parental engagement are still needed.
“As physicians, we must take the lead in speaking openly and compassionately about HPV. It is part of our responsibility to not only treat disease, but to prevent it.”
He notes that even among educated women, awareness about HPV and its link to cervical cancer remains low. Community campaigns, school-based initiatives, and primary care screenings are key tools in closing this gap.
Routine Screenings Still Matter
While the vaccine significantly reduces risk, it does not eliminate the need for routine cervical screening. Pap smears and HPV tests remain essential, especially for women over 30.
“The vaccine is not a replacement for screening,” says Dr. Khalafallah. “Together, they form a powerful shield.”
He recommends that vaccinated women continue with regular gynecological check-ups and screening schedules as advised by their physicians.
Empowering Through Education
At the core of Dr. Khalafallah’s approach is empowerment through education. He encourages women to ask questions, seek reliable information, and be proactive about their health. “Informed women make stronger choices,” he says.
At Al-Ahli Hospital, where Dr. Khalafallah practices, there is a growing emphasis on patient-centered education. Whether through counseling during consultations, community workshops, or informational materials in clinics,
the goal is to normalize conversations around HPV, vaccination, and gynecological health.
Al-Ahli Hospital’s Commitment to Women’s Health
Al-Ahli Hospital is deeply committed to preventive healthcare and women’s wellness. As part of this commitment, HPV vaccination is available and promoted as part of routine preventive care. Gynecology teams work hand-in-hand with the Training & Development and Public Health departments to ensure that healthcare professionals are equipped to educate patients clearly and confidently.
Moreover, the hospital’s status as an accredited CPD center for healthcare professionals ensures that clinical teams remain updated on the latest global guidelines for HPV screening and vaccination strategies.
A Vision for a Cervical Cancer-Free Generation
The World Health Organization has launched a global strategy to eliminate cervical cancer as a public health problem, with targets that include 90% of girls fully vaccinated with the HPV vaccine by age 15. Dr. Khalafallah believes that Qatar can be a regional leader in this effort.
“We have the infrastructure. We have the knowledge. What we need is continued collaboration between healthcare providers, parents, educators, and policymakers.” His vision is bold but achievable: a generation of women in Qatar who grow up protected, empowered, and free from the fear of cervical cancer.
Final Thoughts
Dr. Ahmad Khalafallah’s message is one of science, compassion, and hope: “When we vaccinate a young girl today, we are protecting her from a disease she may never know existed. That is the true power of prevention.” In a world where women’s health is often reactive, HPV vaccination offers a proactive path forward, one that begins with awareness, continues with access, and ends with empowerment.
IN QATAR AND ACROSS THE REGION, PUBLIC HEALTH AUTHORITIES HAVE TAKEN STEPS TO INTRODUCE HPV VACCINATION INTO PREVENTIVE CARE PROGRAMS. DR. KHALAFALLAH SEES THIS AS A CRITICAL STEP, BUT EMPHASIZES THAT GREATER PUBLIC EDUCATION, PHYSICIAN ADVOCACY, AND PARENTAL ENGAGEMENT ARE STILL NEEDED. “AS PHYSICIANS, WE MUST TAKE THE LEAD IN SPEAKING OPENLY AND COMPASSIONATELY ABOUT HPV. IT IS PART OF OUR RESPONSIBILITY TO NOT ONLY TREAT DISEASE, BUT TO PREVENT IT.”
Traveling to Türkiye for Prostate Cancer Treatment: What Acıbadem Offers
Although prostate cancer is the most common cancer in men, the good news is that it is generally treatable. At Acıbadem, we offer both surgical and non-surgical options to cure localized disease permanently. For metastatic prostate cancer, we utilize systemic therapies and targeted radioactive treatments to control cancer progression, relieve symptoms, and enhance the patient’s quality of life.
The prostate is a gland unique to males and is part of the reproductive system. Prostate diseases are common, and the three most frequent conditions are prostate cancer, benign prostatic enlargement, and prostatitis. Each condition is distinct and requires its own treatment approach. Prostate cancer often causes the most concern, since the word “cancer” is frightening for many. Fortunately, when the tumor is localized and confined to the prostate, it is highly treatable today.
Robotic Surgery for Safe and Precise Cancerous Prostate Removal
The gold standard treatment for prostate cancer is surgery, which removes the entire prostate. If the tumor is confined to the prostate, surgery can provide a complete cure. However, preserving the surrounding vessels and nerves responsible for urinary control and erectile function is equally important, as these functions are valuable to a man’s quality of life. Even when the tumor is successfully removed, urinary incontinence can significantly impact daily life and may require further treatment. Erectile dysfunction is another possible side effect that can affect both the patient and his partner. That’s why top urologic oncology centers globally increasingly use robotic systems for radical prostatectomy, enabling more precise surgery.
Within the Acıbadem Healthcare Group, we currently employ robotic-assisted surgery in six hospitals to deliver the best possible
outcomes. Thanks to our urologists’ extensive experience in robotic prostate cancer surgery, we not only remove the cancer entirely but also minimize the risk of urinary incontinence and impotence. Furthermore, at Acıbadem University, there is an official robotic surgery training center that educates surgeons and offers a globally recognized certificate.
Radiotherapy Effectively Treats Localized Prostate Cancer
Acıbadem has been using radiotherapy to treat cancer for over 20 years. Advances in radiation oncology have led to significant improvements in treatment outcomes. Today, radiotherapy is a valuable option for many types of cancer, including prostate cancer. MRI-guided radiotherapy represents one of the most advanced technologies in this field, providing more precise tumor targeting and better protection for healthy tissues compared to conventional CT-guided systems. For localized prostate cancer, MRI-guided radiotherapy achieves success rates similar to surgery. This
ACIBADEM HAS BEEN USING RADIOTHERAPY TO TREAT CANCER FOR OVER 20 YEARS. ADVANCES IN RADIATION ONCOLOGY HAVE LED TO SIGNIFICANT IMPROVEMENTS IN TREATMENT OUTCOMES. TODAY, RADIOTHERAPY IS A VALUABLE OPTION FOR MANY TYPES OF CANCER, INCLUDING PROSTATE CANCER.
Professor Can OBEK
allows the tumor to be completely treated without an incision, offering an effective alternative to radical prostatectomy.
Radiation or Surgery for Prostate Cancer: What’s the Better Option?
Both radiotherapy and surgery have their advantages and disadvantages. Patients should discuss these treatment alternatives with physicians from both disciplines to determine the best option for their condition. It is important to remember that if radiation therapy is chosen instead of surgery, the machine must be equipped with the latest technology to minimize risks to healthy organs and tissues near the prostate, such as the bladder and functional nerves.
However, at the end of the day, patients should feel at ease with their decision. Both treatments have high success rates in achieving a permanent cure when they are administered by experienced specialists with mastery, attentiveness, and patience.
If My Cancer Has Metastasized
The most challenging scenario in prostate cancer is when it spreads to other organs or tissues. The good news is that prostate cancer usually presents symptoms before it metastasizes. Fewer than 10 percent of patients are diagnosed after the cancer has already spread. At that stage, surgery is no longer an option. Instead, medical oncologists focus on controlling the disease using various treatment modalities.
The primary treatment for metastatic prostate cancer is hormone therapy, as prostate cancer is hormone-dependent. However, if the patient has a high tumor burden or the cancer is predicted to follow an aggressive course, chemotherapy may also be administered.
In patients who become resistant to both hormone therapy and chemotherapy, radioactive treatments such as Lutetium-177 PSMA may be considered.
All treatment decisions are based on the patient’s tumor burden, response to previous therapies, and findings from PSMA PET
imaging. At Acıbadem, medical oncologists who specialize in urologic cancers work closely with urologists to determine the best possible treatment plan for each patient.
If you’d like to learn more, visit acibademinternational.com and share your condition with us through the contact form. Our expert team will get in touch with you within a few hours.
THE MOST CHALLENGING SCENARIO IN PROSTATE CANCER IS WHEN IT SPREADS TO OTHER ORGANS OR TISSUES.
Beyond the Promise: A Candid Look at the Cancer Fight, Our Role,
Ali Elhaj, LLM., Ph. D. Healthcare CEO, Board Member. Risk Governance, Forecast. Implementation. Advisor and Strategist.
Tand the
Road Ahead
he battle against cancer is among the most profound stories of modern medicine.
Genomic breakthroughs now allow us to tailor therapies to a patient’s unique genetic code. Immunotherapies are harnessing the body’s defenses with striking efficacy. Robotic surgeries minimize recovery time, and advanced radiotherapies target tumors with precision.
Yet amidst these advances, a persistent question echoes: “If progress is so remarkable, why is there no cure, and why does it always seem five years away?” This skepticism is not ignorance but a reflection of complexity and communication gaps. Addressing it with honesty, empathy, and vision is essential.
The Complexity of the Human Body: Why a Single Cure is a Mirage
The notion of a universal cure rests on a misconception. Cancer is not one disease but many, each with distinct biology even within the same organ. Cancer cells are not foreign invaders but our own cells gone off-center, making targeted destruction without harming healthy tissue an immense challenge.
Hospitals and Caregivers: The Frontline of Trust
In this landscape, hospitals and caregivers must do more than treat; they must reassure. Patients, flooded with information and misinformation, look for clarity. Trust requires:
1. Transparent Communication: Explaining treatment choices, evidence, risks, and personalization.
2. Emotional Support: Integrating psychooncology and peer groups into care.
3. Patient Navigation: Easing the maze of appointments, treatments, and finances.
4. Compassionate Culture: Hospitals must embody clarity and empathy, not just technology.
Trust is the bedrock of effective care.
The System’s Responsibility: Equity in Prevention and Treatment
Breakthroughs mean little if they are
inaccessible. Equity must guide policy and practice, as victories against cancer hinge on prevention and early intervention. This demands:
• Public Health Campaigns: Expanding awareness of screening and risk reduction.
• Access to Diagnostics: Making genomics and pathology available beyond major cities.
• Policy and Funding: Designing insurance and financing systems that guarantee evidence-based treatments regardless of income.
Inequity is not inevitable; it is a system failure. Cancer care must be a right, not a privilege.
The Future of Cancer Research
The horizon brims with possibility:
• Liquid Biopsies: Detecting cancer DNA in blood long before imaging reveals disease.
• AI and Big Data: Predicting responses, identifying patterns, and accelerating discovery.
• Next-Gen Immunotherapies: Engineering immune cells to bypass cancer defenses.
• Tumor Microenvironment Studies: Targeting the ecosystem that enables cancer to thrive.
These innovations will succeed only through partnerships among researchers, clinicians, hospitals, patients, governments, and the private sector.
From Skepticism to Hope
Public skepticism is not cynicism; it is a call to action. Patients demand transparency, equity, and humanity. Cancer is complex, but our resolve must be greater. We must communicate openly, care compassionately, build equitable systems, and pursue innovation relentlessly. The goal is not just a cure, but a future where cancer is managed, feared less, and faced with confidence.
Turning skepticism into hope, and hope into healing, is an urgent, collective responsibility.
